Datasets:

RJuro

/

neuro_patents

like 2

1999-01-27

Y

1. A cancellation system for removing selected signals from a traffic signal prior to decoding in a receiver that receives communication signals from a transmitter (19) over a CDMA air interface, the system comprising: a system input (147) for receiving the communication signals; said system input (147) inputted as input (103) to a traffic signal cancellation system (101) having an output (O) equal to the desired traffic signal minus the unwanted traffic signals; said signal input (147) also inputted as input (63) to a pilot signal cancellation system (61), the system (61) processing the input (63) to remove a global pilot signal and having an output (Oadd) equal to the desired traffic signal minus the global pilot signal; and whereby the output (Oadd) of the pilot signal cancellation system (61) is subtracted from the output (O) of the traffic signal cancellation system (101) to provide the cancellation system output (151). 2. The cancellation system according to claim 1 wherein the traffic cancellation system (101) comprises a desired traffic signal despreader (91) coupled to a sum and dump processor (97) to produce an output (Osd3) and an unwanted traffic signal canceler (1151-n), the despreader (1151-n) comprising: an unwanted traffic signal despreader (1391-n) having a signal input (103) coupled to said system input (63) and a summed output; the unwanted traffic signal despreader (1391-n) comprising an unwanted traffic signal code generator (1191-n) and a mixer (1171-n) for mixing an output of the generator (1191-n) with the input (103) to produce a unwanted traffic signal canceler output; said unwanted traffic signal despreader summed output coupled to a hard decision processor (1251-n) having a phase output (phi) and a data output (d); said hard decision processor phase output (phi) coupled to a low pass filter (1271-n), said low pass filter having an output (Olpfn); said low pass filter (1271-n) output (Olpfn) coupled to an input of a processor (1291-n) that filters the product of the unwanted traffic signal to desired traffic signal cross-correlation outputting the unwanted traffic signal strength; said processor (1291-n) output multiplied with said hard decision data output (d) with a first multiplier (1311-n) having an output delivered to an adjustable amplifier (1371-n); an unwanted traffic code generator (119) output coupled to an input of a complex conjugate processor (1351-n) having an output; said complex conjugate output mixed with a complex conjugate of the desired traffic signal code by a first mixer (1331-n) having an output; said first mixer (1331-n) output coupled to an input of a first sum and dump processor (1231-n) having an output; said first sum and dump processor (1231-n) coupled to an input of an amplifier (1371-n) having an adjustable gain controlled by said multiplier (1311-n) output; and said output of said amplifier (1371-n) is coupled to an adder (143) which subtracts the output (1411-n) of each variable amplifier (1371-n) from the output (Osd3) of the desired traffic signal despreader (91) to get the output (O) of the traffic signal cancellation system (101). 3. The cancellation system according to claim 1 wherein the pilot signal cancellation system (61) comprises: a global pilot despreader (65) coupled to said input (63) having a summed output (Osd1); a desired traffic signal and global pilot cross-correlation means having an output (Osd2); said global pilot despreader (65) output (Osd1) coupled to a pilot strength determining means, said determining means having an output (Opm); said pilot strength determining means output (Opm) multiplied with said cross-correlation means output (Osd2); and said multiplied product is said output (Oadd). 4. The cancellation system according to claim 3 wherein said cross-correlation means comprises: a global pilot spreading code complex conjugate code generator (69); a desired traffic signal complex conjugate code generator (79); a second mixer (81) for cross-correlating said global pilot signal code and said desired traffic signal complex conjugate code; and a second sum and dump processor (85) for summing over time said cross-correlation product. 5. The cancellation system according to claim 4 wherein said means to derive said global pilot signal strength further comprises: a low-pass filter (75) having an output (Olpf); and a processor (77) coupled to said low-pass filter (75) deriving and outputting the global pilot signal strength. 6. A global pilot signal cancellation system (61) for use in a receiver that receives communication signals from a transmitter over a CDMA air interface that removes the global pilot signal from a desired traffic signal prior to decoding, the system comprising: an input (63) for receiving the communication signals and a system output (Oadd); said input coupled to a global pilot despreader (65) and a desired traffic signal despreader (91) each having a summed output a desired traffic signal and global pilot cross-correlation means; said global pilot despreader (65) output (Osd1) coupled to a pilot strength determining means, said determining means having an output (Opm); said pilot strength determining means output (Opm) multiplied with said cross-correlation means output (Osd2); and said multiplied product subtracted from a summed output (Osd3) of said desired traffic signal despreader (91) output outputting (Oadd) the desired traffic signal free from the global pilot signal. 7. The global pilot signal cancellation system (61) according to claim 6 wherein said means to derive said global pilot signal strength further comprises: a low-pass filter (75) having an output (Olpf); and a processor (77) coupled to said low-pass filter (75) deriving and outputting the global pilot signal strength (Opm). 8. A traffic signal cancellation system (101) for use in a receiver that receives communication signals from transmitter (19) over a CDMA air interface that removes at least one unwanted traffic signal from a desired traffic signal prior to decoding, the system comprising: an input (103) for receiving the communication signals and a system output (O); said input (103) coupled to a desired traffic signal despreader (91) having a first summed output (Osd3); an at least one unwanted traffic signal canceler (1151-n) comprising: an unwanted traffic signal despreader (1391-n) having an input coupled to said first summed output and a second summed output; the unwanted traffic signal despreader (1391-n) comprising an unwanted traffic signal code generator (1191-n) and a mixer (1171-n) for mixing an output of the generator (1191-n) with the input (103) to produce a unwanted traffic signal despreader output; said unwanted traffic signal despreader (1391-n) summed output coupled to a hard decision processor (1251-n) having a phase output (phi) and a data output (d); said hard decision processor (1251-n) phase output (phi) coupled to a low pass filter (1271-n), said low pass filter (1271-n) having an output (Olpfn); said low pass filter (1271-n) output (Olpfn) coupled to an input of a processor (1291-n) that filters the product of the unwanted traffic signal to desired traffic signal cross-correlation outputting the unwanted traffic signal strength; said processor (1291-n) output multiplied with said hard decision data output (d) with a multiplier having an output delivered to an adjustable amplifier (1371-n); an unwanted traffic code generator (1191-n) output coupled to an input of a complex conjugate processor (1351-n) having an output; said complex conjugate output mixed with a complex conjugate of the desired traffic signal code by a mixer (1331-n) having an output; said mixer (1331-n) output coupled to an input of a second sum and dump processor (1231-n) having an output; said second sum and dump processor (1231-n) coupled to an input of an amplifier (1371-n) having an adjustable gain controlled by said multiplier (1311-n) output; and said output of said amplifier (1371-n) is coupled to an adder (143) which subtracts the output (1411-n) of each variable amplifier (1371-n) from the output (Osd3) of the desired traffic signal despreader (91) to get the output (O) of the traffic cancellation system (101). 9. The cancellation system according to claim 6 wherein said cross-correlation means comprises: a global pilot signal code generator (65); a desired traffic signal complex conjugate code generator (79); a second mixer (81) for cross-correlating said global pilot signal code and said desired traffic signal complex conjugate code; and a second sum and dump processor (85) for summing over time said cross-correlation product. 10. The cancellation system according to claim 9 wherein said means to derive said global pilot signal strength further comprises: a low-pass filter (75) having an output; and a processor (77) coupled to said low-pass filter (75) deriving and outputting the global pilot signal strength. 11. A method for cancelling a global pilot signal from a desired traffic signal, comprising: providing an input for receiving communication signals from a transmitter over a CDMA air interface; said input coupled to a global pilot despreader (65) and a desired traffic signal despreader (91) each having a summed output; identifying a desired traffic signal and provides a global pilot cross correlation means; said global pilot despreader (65) output coupled to a pilot strength determining means having an output, said pilot strength determining means output multiplied with said cross-correlation means output where said cross-correlation means comprising; and said multiplied product subtracted from said desired traffic signal despreader output and outputting the desired traffic signal free from the global pilot signal. 12. The method according to claim 11 wherein said means to derive said global pilot signal strength further comprises: a low-pass filter having an output, and a processor coupled to said low-pass filter (75) derivi

en

CANCELLATION OF PILOT AND UNWANTED TRAFFIC SIGNALS IN A CDMA SYSTEM

64768944_US

65355626_US

H04B 1/7097,H04B 1/7103,H04B 1/7107,H04B 1/71075,H04B2201/70701

1998-12-08

Y

1. A compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH- or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 2. A compound of Claim 1 wherein Ar' is phenyl or pyridine. 3. A compound of Claim 2 wherein Ar' is phenyl substituted with (C1-C6)alkoxy. 4. A compound of Claim 3 wherein R<2> is phenyl or (C3-C12)cycloalkyl. 5. A compound of Claim 4 wherein R<1> is hydrogen. 6. A compound of Claim 5 wherein X is -C=O. 7. A method of antagonizing the serotonin 1A receptor which comprises administering to a patient in need of such treatment an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 8. A method of alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine which comprises the administration to a patient in need of such treatment of an effective amount of a compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 9. A method of Claim 8 wherein the compound is 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine; 1-(2-pyridyl)-4-[3-(cyclohexanecarbonyl)-3-(phenyl)propyl]piperazine; 1-(2-ethoxyphenyl)-4-[3-(cyclohexanecarbonyl)-3-(phenyl)propyl]piperazine hydrochloride; 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)butyl]piperazine oxalate; 1-(2-methoxyphenyl)-4-[3-(cycloheptanecarbonyl)-3-(phenyl)propyl]piperazine hydrochloride; 1-(2-methoxyphenyl)-4-[3-(cyclopentanecarbonyl)-3-(phenyl)propyl]piperazine hydrochloride; and 1-(2-methoxyphenyl)-4-[4-(cyclohexyl)-4-(hydroxy)-3-(phenyl)butyl]piperazine oxalate. 10. A method of treating anxiety comprising administering to a patient in need of such treatment an effective amount of a compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH- or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 11. A method of treating depression, hypertension, cognitive disorders, psychosis, sleep disorders, gastric motility disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, obsessive-compulsive disease, panic disorder or migraine, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH- or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 12. A method for potentiating the action of a serotonin reuptake inhibitor in increasing the availability of serotonin, norepinephrin and dopamine in the brain, comprising administering to a patient in need of such treatment a serotonin reuptake inhibitor in combination with an effective amount of a compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH- or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1. 14. A method of Claim 8 wherein an effective amount of a serotonin reuptake inhibitor is administered. 15. A method of Claim 14 wherein the serotonin reuptake inhibitor is fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine or paroxetine. 16. A method of assisting a patient in ceasing or reducing their use of tobacco or nicotine comprising administering to a patient an effective amount of a compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH- or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 17. A compound of the formula: or the pharmaceutically acceptable salts thereof. 18. A compound which is (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine and the pharmaceutically acceptable salts thereof. 19. A compound according to claim 18 wherein the pharmaceutically acceptable salt is a dihydrochloride salt. 20. A compound according to claim 18 wherein the pharmaceutically acceptable salt is an oxalate salt. 21. A compound according to claim 18 wherein the pharmaceutically acceptable salt is a maleate salt. 22. A compound according to claim 18 wherein the pharmaceutically acceptable salt is a phosphate salt. 23. A compound which is (+) -1-(2-methoxyphenyl)-4-[3-(cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine monohydrochloride. 24. A method of alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine which comprises the administration to a patient in need of such treatment of an effective amount of a compound of the formula: or the pharmaceutically acceptable salts thereof. 25. A method of alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine which comprises the administration to a patient in need of such treatment of an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or the pharmaceutically accepta

en

ARYLPIPERAZINES HAVING ACTIVITY AT THE SEROTONIN 1A RECEPTOR

64504836_US

68156489_US,68325384_US,68340107_US,69223679_US,69734728_US

A61K 31/495,A61K 31/496,A61P 1/00,A61P 3/04,A61P 9/00,A61P 9/12,A61P 15/10,A61P 25/00,A61P 25/06,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/30,A61P 25/34,A61P 43/00,C07C 45/004,C07C 45/29,C07C 45/40,C07C 45/515,C07C 45/59,C07C 45/68,C07C 49/563,C07C 49/577,C07C 49/583,C07C 49/86,C07D 213/74,C07D 295/088,C07D 295/092,C07D 295/104,C07D 295/108

2000-02-02

Y

1. A compound of the formula wherein A and B rings are phenyl rings; n and m are, selected, independently, from one, two and three; R<1> and R<2> are selected, independently, from hydrogen, (C1-C4) alkyl, (C2-C4) alkenyl, and (C2-C4) alkynyl, or R<1> and R<2> together with the nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<1> and R<2> are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6) alkyl; R<3> and R<4> are selected, independently, from hydrogen and (C1-C4) alkyl optionally substituted with from one to three fluorine atoms, or R<3> and R<4> together with the carbon to which they are attached, form a four to eight membered saturated carbocyclic ring, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6) alkyl; or R<2> and R<3>, together with the nitrogen to which R<2> is attached and the carbon to which R<3> is attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<2> is attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6) alkyl; each X is selected, independently, from hydrogen, halo (i. e., chloro, fluoro, bromo or iodo), (C1-C4) alkyl optionally substituted with from one to three fluorine atoms, (C1-C4) alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, (C1-C4) alkylamino, di-[(C1-C4)alkyl]amino, NR<5>(C=O)(C1-C4) alkyl, SO2NR<5>R<6> and SO2(C1-C6) alkyl, wherein R<5> and R<6> are selected, independently, from hydrogen and (C1-C6) alkyl, and p is zero, one or two; and each Y is selected, independently, from hydrogen, (C1-C6) alkyl and halo; with the proviso that: (a) no more than one of NR<1>R<2>, CR<3>R<4> and R<2>NCR<3> can form a ring; and (b) at least one X must be other than hydrogen when (i) R<3> and R<4> are both hydrogen, (ii) R<1> and R<2> are selected, independently, from hydrogen and (C1-C4) alkyl, and (iii) ring B is mono- or disubstituted with, respectively, one or two halo groups; or a pharmaceutically acceptable salt thereof. 2. A compound or salt according to claim 1, wherein n is one, X is fluoro, R<3> and R<4> are hydrogen, R<1> is hydrogen, R<2> is methyl, m is two and Y is Ym is 3,4-dichloro. 3. A compound or salt according to claim 1, wherein m is zero, n is one, R<3> and R<4> are hydrogen, X is chloro, bromo, iodo or methyl, R<1>is hydrogen and R<2> is methyl. 4. A compound or salt according to claim 1, wherein said compound or salt is selected from the following compounds and their pharmaceutically acceptable salts: [2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-dimethylamine; [2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-methylamine; [2-(3,4-Dichlorophenoxy)-5-trifluoromethylbenzyl]-dimethylamine; N-[4-(3,4-Dichlorophenoxy)-3-dimethylaminomethylphenyl]-acetamide; {1-[2-(3,4-Dichlorophenoxy) phenyl]-ethyl}-dimethylamine; [2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-dimethylamine; [2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-methylamine; [4-Chloro-2-(3,4-dichlorophenoxy)-benzyl]-methylamine; {1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine; {1-[2-(3,4-Dichlorophenoxy)phenyl}-ethyl}-methylamine; {1-[2-(4-Chlorophenoxy)phenyl]ethyl}-methylamine; [2-(3, 4-Dichlorophenoxy)-5-methoxybenzyl]-methylamine; [2-(4-Chlorophenoxy)-5-fluorobenzyl]-methylamine; {1-[2-(4-Chlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine; [2-(3,4-Dichlorophenoxy)-5-methylbenzyl]-dimethylamine; [4-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine; [5-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine; [2-(3,4-Dichlorophenoxy)-4,5-dimethoxybenzyl]-methylamine; [2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-dimethylamine; 4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-benzonitrile; [2-(3,4-Dichlorophenoxy)-4,5-dimethylbenzyl]-methylamine; 3-(3,4-Dichlorphenoxy)-4-methylaminomethyl-benzonitrile; (+)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine; (-)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine; [2-(3,4-Dichlorophenoxy)-5-trifluoromethyl-benzyl]-methylamine; [2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-methylamine; [2-(4-Chloro-3-fluorophenoxy)-5-fluorobenzyl]-methylamine; [2-(3-Chloro-4-fluorophenoxy)-5-fluorobenzyl]-methylamine; (+/-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine; (-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine; (+)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine; and 2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-N-methylpyrrolidine. 5. A pharmaceutical composition for treating a disorder or condition selected from hypertension, depression, (depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, in a mammal, preferably a human, comprising an amount of a compound according to claim 1 that is effective in treating such disorder or condition and a pharmaceutically acceptable carrier. 10. A pharmaceutical composition for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, preferably a human, comprising an amount of a compound of the formula 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition and a pharmaceutically acceptable carrier. 11. A method for treating a disorder or condition selected from hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder in a mammal, preferably a human, comprising an amount of a compound according to claim 1 that is effective in treating such disorder or condition and a pharmaceutically acceptable carrier. 12. A method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1, that is effective in treating such disorder or condition. 13. A pharmaceutical composition for treating a condition or disorder that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising: a) a pharmaceutically acceptable carrier; b) a compound according to claim 1; and c) an NK-1 receptor antagonist or a 5HT1D receptor antagonist, or a pharmaceutically acceptable salt thereof; wherein the amount of the active compounds (i. e., the compound of formula I and the NK-1 receptor antagonist or <5>HT1D receptor antagonist) are such that the combination is effective in treating such disorder or condition. 14. A method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising administering to a mammal requiring such treatment: a) a compound of the formula 1, defined above, or a pharmaceutically acceptable salt thereof; and b) an NK-1 receptor antagonist or 5HT1D receptor antagonist, or a pharmaceutically acceptable salt thereof; wherein the amounts of the active compounds (i. e., the compound of formula I and the NK-1 receptor antagonist or 5HT1D receptor antagonist) are such that the combination is effective in treating such disorder or condition.

en

MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS

64994367_US

67776770_US,64742870_US,68570245_US,69732263_US

A61P 1/04,A61P 3/04,A61P 5/00,A61P 9/12,A61P 13/10,A61P 15/10,A61P 17/14,A61P 25/00,A61P 25/06,A61P 25/08,A61P 25/16,A61P 25/18,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/30,A61P 25/32,A61P 25/34,A61P 25/36,C07C 217/58,C07C 217/90,C07C 233/18,C07C 235/34,C07C 255/37,C07C 255/59,C07C 311/29,C07C 317/32,C07C 323/20,C07D 207/08,C07D 211/22,C07D 265/30,C07D 279/12,C07D 295/096

1999-03-24

Y

1. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 2. A method of claim 1, wherein said dose of cabergoline is about 0.1 to 6 mg per patient per administration, on an as needed basis. 3. A method of claim 2 wherein said dose of cabergoline is administered once a day. 4. A method of claim 2 wherein said dose of cabergoline is administered 4 or 5 times a week in amounts from about 0.25 to 6 mg per administration. 5. A method of claim 2 wherein said dose of cabergoline is administered 2 or 3 times a week in amounts from about 0.25 to 6 mg per administration. 6. A method of claim 5 wherein said dose of cabergoline is administered once a week in amounts from about 0.25 to 6 mg per administration. 7. A method of claim 1, wherein said dose of Cabergoline is about 0.25 to 4 mg/day. 8. A method of claim 1, wherein said dose of Cabergoline is about 0.25 to 2 mg/day. 9. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, who has previously been treated, or is concurrently being treated with one or more of; a dopamine agonist, a benzodiazepine, or a psychotropoic agent, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 10. A method of claim 9, wherein the previous or concurrent treatment is or was with a dopamine agonist and the dose of Cabergoline is about 0.1 to 6 mg/day. 11. A method of claim 9, wherein said dopamine agonist is or was levodopa. 12. A method of claim 11, wherein said dose of Cabergoline is about 0.25 to 4 mg/day. 13 A method of claim 9, wherein said previous or concurrent treatment is or was with a benzodiazepines and said dose of Cabergoline is about 0.25 to 4 mg/day. 14. A method of claim 13, wherein said benzodiazepine is clonazepam (Klonopin). 15. A method of claim 9, wherein said previous or concurrent treatment is or was with said psychotropoic agent, wherein said psychotropoic agent is an opioid and said dose of Cabergoline is about 0.1 to 4 mg/day. 16. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, where the patient has suffered from or is considered susceptible to suffer from agumentation or rebound effects from a previous treatment for RLS wherein the previous treatment consists of being treated with one or more of ; a dopaminergic agent, a dopamine agonist, a benzodiazepine, or a psychotropoic agent, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 17. A method for treating patients who are not sleeping well, comprising the adminstration of an effective amount of cabergoline or its pharmaceutically acceptable salts. 18. A method of claim 17 where said patients have an abnormal sleep pattern as measured by standard sleep tests. 19. A method of claim 16 where said effective amount of cabergoline is between about 0.25 to 5 mg per patient per day. 20. A method of claim 16 where said previous treatment consisted of being treated with a dopamine agonist, wherein said dopamine agonist is levodopa and said effective amount of cabergoline or salt thereof is from 0.25- 4 mg per patient per day. 21. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, where the patient has suffered from tolerance from a previous treatment for RLS wherein the previous treatment consisted of being treated with one or more of; a dopaminergic agent, a dopamine agonist, a benzodiazepine, or a psychotropoic agent, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 22. A method of claim 21 where said previous treatment consisted of being treated with a dopamine agonist, wherein said dopamine agonist is levodopa and said effective amount of cabergoline or salt thereof is from 0.1- 4 mg per patient per day. 23. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof in combination with an effective amount of levodopa or its pharmacologically acceptable salts. 24. A once a day method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof to the patient, once a day. 25. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof, but without the administration of another dopaminergic agent. 26. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, consisting essentially of: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 27. Any treatments of claims 1-26 where the cabergoline is administered to the patient once a day. 28. Any treatments of claims 1-26 where the cabergoline is administered to the patient every other day. 29. Any treatments of claims 1-26 where the cabergoline is administered to the patient about 2-3 times per week. 30. The use of cabergoline or its pharmaceutically acceptable salts in the manufacture of a medicament to treat RLS, and for any of the RLS symptoms described herein.

en

USE OF CABERGOLINE IN THE TREATMENT OF RESTLESS LEGS SYNDROME

15604703_US,68170275_US

64257288_DE

A61K 31/48,A61K 31/485,A61K 31/55,A61K 45/06,A61P 25/00,A61P 25/02,A61P 25/14,A61P 25/20,A61P 43/00,Y10S 514/923

2018-03-29

N

Receive, from the base station. based on the unnsmitted ACID NACK feedback, a retransmission of one of the set of CBEs or the fir. subset of CBe r s Receive, from a base station, a set of CBGs including a first subset of (Bilis and a second subset of CB(is, the first subset of CB( is laving been transmitted on at least partially punctured resources I Reeeicen mdlcator indicant, the at least p Ily 1004 ,Lune resouce, Decode the set of [Reis Transmd, to the base station, an ACK/NACK feedback based on the decoding 1006 1008 1002 1010 Receive from the base station, in a retrammission 1012 L grant. CBG fist dad a retransmission type indicator s W O 20 18/187 163 Al ......i... m r .. T 02 41 ... 014 first subset Adl set of of type indicator indicntes ...\'-- ..... CBCts retransmission of the ed of CBGs or ...-- •••• w . the first subset of CBSis.--\'..\' 11022 rDetemnne. based on the mtransmramcal iDetermtne, based on the =MS1311.100 tyPI I type indiCE.,118t II, CBG RC I indicator, that the CBG list indicates CBGs I I Indicates CBGs for which previously I l_blinlrarMs.ttted . theeLlanZnissiee_ I I gored I I It v sluesaonld I, nulled I f — / 1(7[3 — i 1024 I Determine dam ilt' CBGs indiCaleerm — the - I E Decode the retransmitted f • subset 1 I CBG list correspond to CB(rs which failed I I of CBGs •,,illeut perfornung soft . I the deccdinL I I umnbining based on the prusiousJy + 020 I stored LLB values a - the first subset ) of CBGs I r Decode., in response to detcrnining that the L 3 _,1026 I CMGs in fi ll ' ne°P°33 ' dno I r Decode the retransmitted second I :he CBG. Ini • r the I ....tr...., arse wths „ t wt ., w ith out I I subaet of CBCrsuab soil g 1 iperfirming soft combining based on preriouly I I based on previously stored LLR stored 1.1-R verses for . .he first subset of CFSt • I slues for the second subset of CBGs FIG. 10 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit VIII °nolo III OH mom VIII 10110111110 mil (10) International Publication Number WO 2018/187163 Al (51) International Patent Classification: HO4L 1/18 (2006.01) (21) International Application Number: PCT/US2018/025229 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/481,089 03 April 2017 (03.04.2017) US 15/939,165 28 March 2018 (28.03.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTEN: International IP Administration, 5775 Morehouse Drive, San Diego, California, US 92121-1714 (US). (72) Inventors: SUN, Jing; c/o QUALCOMM INCORPO- RATED, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). JIANG, Jing; c/o QUALCOMM IN- CORPORATED, 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). (74) Agent: HODGES, Jonas J. et al.; c/o Arent Fox LLP, 1717 K Street NW, Washington, District of Columbia 20006-5344 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: FEEDBACK FOR CODEBLOCK GROUP BASED TRANSMISSIONS (57) : Various features related to a single bit ACK/NACK feedback for CBG based transmissions in a communication system are described. In an aspect, a base station may transmit, to a UE, a set of CBGs of a TB including a first subset of CBGs and a second subset of CBGs, the first subset of CBGs being transmitted on at least partially punctured resources. The base station may receive an ACK/NACK from the UE based on the transmitted set of CBGs, and retransmit to the UE one of the full set of CBGs or the first subset of CBGs based the received ACK/NACK. In an aspect, a UE may decode the set of CBGs received from the base station, transmit ACK/NACK feedback based on a result of the decoding, and receive, based on the transmitted ACK/NACK feedback, a retransmission of either the full set of CBGs, or the first subset of CBGs. [Continued on next page] WO 2018/187163 Al Dill Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

FEEDBACK FOR CODEBLOCK GROUP BASED TRANSMISSIONS

52280328_US

56459191_US,69733127_US

H03M 13/1111,H04L 1/0013,H04L 1/1819,H04L 1/1861,H04L 1/1864,H04L 5/0048,H04L 5/0055

2018-02-23

N

Transmit the SR with the ACK / NACK FIG. 20 Receive one or more downlink transmissions from a base station Determine to transmit an uplink transmission to the base station Jr_ I Determine whether to transmit the scheduling 2006 I request with the ACK / NACK or to transmit the r I scheduling request using dedicated resource r Perform QPSK mapping of a fast bit value I assodated with the scheduling request and a second r\'\' I bit value associated with the ACK / NACK r Perform at least one of channel coding or data I scrambling of the scheduling request and the ACK / 1 1 3 - 10 NACK after the QPSK mapping 1 Perform BPSK mapping of the second hit value 12012 associated with the ACK/NACK I II Determine if the scheduling request is transmitted 13 014 with the ACK / NACK 1 i 2002 2004 e' r I Shift the BPSK mapping of the second bit value 2016 I associated with the ACK / NACK by 90 .1 or another I predetermined angle L J lr 2000 W O 20 18/ 175 0 42 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIPO I PCT (51) International Patent Classification: H04L 5/00 (2006.01) HO4W 72/12 (2009.01) H04W 52/50 (2009.01) H04W 74/00 (2009.01) (21) International Application Number: PCT/US2018/019535 (22) International Filing Date: 23 February 2018 (23.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201741010253 23 March 2017 (23.03.2017) IN 201741016601 11 May 2017 (11.05.2017) IN 15/718,418 28 September 2017 (28.09.2017) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; Atten: International IP Administration, 5775 Morehouse Drive, San Diego, California, US 92121-1714 (US). (72) Inventors: WANG, Xiao feng; c/o Qualcomm Incor- porated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). RICO ALVARINO, Alberto; c/o Qual- comm Incorporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). BHATTAD, Kapil; c/o Qual- comm Incorporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). XU, Hao; c/o Qualcomm In- corporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: HODGES, Jonas J. et al.; c/o Arent Fox LLP, 1717 K Street NW, Washington, District of Columbia 20006-5344 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: SCHEDULING REQUEST FOR ONE OR MORE UPLINK TRANSMISSIONS USING NARROWBAND COMMUNI- = CATIONS 011101 V III o Ho ilom No VII IE (10) International Publication Number WO 2018/175042 Al (57) : The present disclosure may support dedicated scheduling re- quest resources in a NPUSCH format resource structure, a NPRACH, and/ or an ACK / NACK transmission associated with a downlink transmission received at the UE. In addition, the present disclosure may provide various techniques to mitigate collisions between scheduling requests transmitted by a UE, uplink transmissions sent by different UEs, and/or downlink transmis- sions sent by a base station. In an aspect of the disclosure, a method, a com- puter-readable medium, and an apparatus are provided. The apparatus may receive one or more downlink transmissions from a base station. The appa- ratus may determine to transmit an uplink transmission to the base station. The apparatus transmit, to the base station, a scheduling request for the uplink transmission with an ACK / NACK associated with the one or more downlink transmissions using a narrowband NPUSCH format resource structure. [Continued on next page] WO 2018/175042 Al MIDEDIMOMMIDIREIDIOMMEEINNIEHIMEMOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

SCHEDULING REQUEST FOR ONE OR MORE UPLINK TRANSMISSIONS USING NARROWBAND COMMUNICATIONS

52280328_US

71790391_US,68937361_US,56570006_US,67553613_US

H04L 1/1671,H04L 1/18,H04L 1/1854,H04L 1/1861,H04L 1/1896,H04L 5/0007,H04L 5/0053,H04L 5/0055,H04L 27/18,H04W 28/06,H04W 72/12,H04W 72/1284,H04W 76/27,H04W 88/02

2017-10-26

N

12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111 RH 0 HI 010 IIM IV I I 0 101110 Ell 1101E1011H MI 1111 1111 Organization International Bureau (10) International Publication Number International Publication Date ......0\'\'1 WO 2018/078053 Al 03 May 2018 (03.05.2018) WIP0 I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) International Patent Classification: PEUTICS INC. [CA/CA]; 2714 West 31st Avenue, Van- A61K 39/12 (2006.01) A61K 47/18 (2017.01) couver, British Columbia V6L 2A1 (CA). A61K 39/39 (2006.01) A61K 9/127 (2006.01) (72) Inventors: BAUMHOF, Patrick; Erlenstr. 28, 72144 Dus- A61P 31/16 (2006.01) CO7C 219/06 (2006.01) A61P 31/14 (2006.01) CO7C 229/16 (2006.01) slingen (DE). FOTIN-MLECZEK, Mariola; Chemnitzer A61K 9/51 (2006.01) CO7C 233/18 (2006.01) Weg 10, 71065 Sindelfmgen (DE). HEIDENREICH, A61K 31/225 (2006.01) CO7C 255/24 (2006.01) Regina; BirkenstraBe 15, 72072 Tubingen (DE). HOPE, A61K 9/16 (2006.01) Michael J.; 3550 West 11th Avenue, Vancouver, British Columbia V6R 2K2 (CA). JASNY, Edith; Mohringer Str. International Application Number: 159, 70199 Stuttgart (DE). LAZZARO, Sandra; Michael- PCT/EP2017/077517 str. 9, 72070 Tiibingen (DE). LIN, Paulo Jia Ching; 2837 E. 54th Ave., Vancouver, British Columbia V5S 1Y4 (CA). International Filing Date: LUTZ, Johannes; HauBer Str. 142, 72076 Tiibingen (DE). 26 October 2017 (26.10.2017) MUI, Barbara; 1158 East 11th Avenue, Vancouver, British English Columbia V5T 2G3 (CA). PETSCH, Benjamin; Hagel- Publication Language: English locher Weg 44, 72070 Tubingen (DE). RAUCH, Susanne; Im Winkelrain 18, 72076 Tiibingen (DE). SCHMIDT, Kim Priority Data: Ellen; Talstr. 27, 72135 Dettenhausen (DE). TAM, Ying; PCT/EP2016/075843 3575 West 19th Avenue, Vancouver, British Columbia V6S 26 October 2016 (26.10.2016) EP 1C3 (CA). PCT/EP2016/075929 (74) Agent: PHARMA CONCEPTS GMBH; Unterer Rhein- 27 October 2016 (27.10.2016) EP weg 50, 4057 Basel (CH). PCT/EP2017/064066 09 June 2017 (09.06.2017) EP (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, Applicants: CUREVAC AG [DE/DE]; Paul-Ehrlich- AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, StraBe 15, 72076 Tubingen (DE). ACUITAS THERA- CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, EEEEE 7 S Y, ii 2 , g O -. . s a a an of (54) Title: LIPID 1.1o.- lx1C - c ix106- 1?) E 1,105- 1x10\' - 1x10 .3 NANOPARTICLE MRNA VACCINES PpLuc expression i.m. - 24h , A _ ixioB 'Ix A.R 4 1. A. • .. - § 1 • • .—. 1 , ,p • 118- s 1,10 7 • • - , 3 - 3 Is * ¨ 4 ci, ' c • , g g ix106 • '2 0, s 1,105 o_ o_ 1x10\' 1x10 3 PpLuc expression i.m. - 48h 4.-4,A 41-* • 4 4 * ;1. .• . .. 1 • -W- — ¨ .4. * :70. • • ¨ - 0 4 0 , , 0 ti0 A 4f ,, , > 0 ) .s> 4 ,zs f> , ,> ff 4S s p s Of A A A A A 4 A 4 A A ti ~4 's , • 's , p. 's , , c,,'\' 's ,C) . '' , s p4 , , ,s2 0 , 4 \ p4 . , ,,A , ,s2 , , p,s2 , , y 4 c) , , p4 A • • ;SY . c > t ' ) \'›.. ''). ob . , SO - ' 4: NS ) p' \'; .es.%'' , f,' ' GA 0 R V ' c k e ,o , , ,,, of' , , z sY A N- 0 e \,‘ 0 N . ,' N3- \ O ,o6 ° CP S c FIG. 1A FIG. 113 : The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination. ,—, M un C> VD IN c: : :: , (57) -- -- GC present ,1 as 0 use ei C [Continued on next page] WO 2018/078053 Al MIDEDIMOMOIDEIREIDIONOMMOIREIMOVOIS DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))

en

LIPID NANOPARTICLE MRNA VACCINES

71485142_CA,56227581_DE

56309438_DE,71104339_DE,57510297_DE,71935644_DE,71060926_CA,71710262_DE,71708492_DE,71639113_CA,56506012_DE,71164987_CA,56480518_DE,64601951_DE,71831033_CA

A61K 9/1272,A61K 9/19,A61K 9/5123,A61K 31/16,A61K 31/23,A61K 31/40,A61K 31/7105,A61K 39/12,A61K 39/145,A61K 39/385,A61K 39/39,A61K 47/14,A61K 47/6929,A61K2039/53,A61K2039/54,A61K2039/55555,A61K2039/6018,A61K2039/70,A61P 31/14,A61P 31/16,A61P 37/02,B82Y 5/00,C07C 211/21,C07C 219/06,C07C 219/08,C07C 229/16,C07C 233/18,C07C 233/36,C07C 255/24,C07C2601/14,C12N2760/16134,C12N2760/16234,C12N2760/20134

2018-04-11

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT omit VIII °nolo VIII miono Hs (10) International Publication Number WO 2018/194523 Al (51) International Patent Classification: G16H 50/30 (2018.01) (21) International Application Number: PCT/TH2018/000019 (22) International Filing Date: 11 April 2018 (11.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1701002141 19 April 2017 (19.04.2017) TH (71) Applicants: NATIONAL SCIENCE AND TECHNOL- OGY DEVELOPMENT AGENCY [TH/TH]; 111 Thai- land Science Park, Phahonyothin Road, Khlong 1, Khlong Luang, Pathum Thani, 12120 (TH). SOFTWARE ISARA ORDINARY PARTNERSHIP [TH/TH]; 64/43 Soi Lad- phrao 83, Ladprao Road, Wangthonglang, Bangkok, 10310 (TH). (72) Inventors: THIEMJARUS, Surapa; 111 Thailand Science Park, Phahonyothin Road, Khlong 1, Khlong Lu- ang, Pathum Thani, 12120 (TH). ANANTAVRASILP, Isara; 64/43 Soi Ladphrao 83, Ladprao Road, Wangth- onglang, Bangkok, 10310 (TH). (74) Agent: RUANGSIN, Ratchada et al.; 111 Thailand Science Park, Phahonyothin Road, Khlong 1, Khlong Lu- ang, Pathum Thani, 12120 (TH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: SYSTEM FOR RECORDING, ANALYZING RISK(S) OF ACCIDENT(S) OR NEED OF ASSISTANCE AND PROVIDING REAL-TIME WARNING(S) BASED ON CONTINUOUS SENSOR SIGNALS (57) : This invention relates to a system for recording, analyzing risk(s) of accident(s) or need of assistance and providing real-time warning(s) based on continuous sensor signals, wherein the system according to this invention comprising at least one mea- suring device(s) and at least one administrative device(s), wherein the said measuring device(s) receives various data related to the user for processing and displaying on the administrative device(s). More complex system may comprise of at least one signal fusion device(s) for transferring data related to the examinee(s), for a wider area of coverage, and/or at least one server(s) that records various data related to the examinee and administrator(s), in order to playback, process and/or transfer data to other administrative device(s) or transfer warning data to relative(s) of the examinee. The data analytical-processing step may be performed on the measuring device(s) itself or distributed to various parts of the system. Wherein said data processing step comprises a data processing and displaying step, which further comprising a data input step, a context recognition step, an inference for estimating risk and a warning step, a database record step, a display step, and a warning configuration step. The system for recording, analyzing risk(s) of accident(s) or need of assistance and providing real-time warning(s) based on continuous sensor signals according to this invention can continuously notify various data measurement and analysis related to the examinee and warn the administrator(s) when the examinee is at risk as identified in the system for a particular examinee. This allows the administrator(s) to help or adjust the state of the examinee appropriately, in order to reduce a chance of unwanted incidents that may happen to the examinee. Moreover, the measured data can also be used by physician(s) or the administrator(s) to analyze for diagnosis, treatment and caring methods for the examinee.

en

SYSTEM FOR RECORDING, ANALYZING RISK(S) OF ACCIDENT(S) OR NEED OF ASSISTANCE AND PROVIDING REAL-TIME WARNING(S) BASED ON CONTINUOUS SENSOR SIGNALS

74318072_TH,74315788_TH

74122855_TH,73895769_TH

A61B 5/1117,A61B 5/112,A61B 5/742,A61B 5/7455,A61B 5/746,G08B 21/0446,G08B 21/0453,G16H 50/30

2017-10-27

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111011101 HIM 0110100111111111 H1111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\' WO 2018/085149 Al 11 May 2018 (11.05.2018) WIPO I PCT (51) International Patent Classification: California 92121-1714 (US). KADOUS, Tamer; c/o H04W 72/04 (2009.01) QUALCOMM INCORPORATED, 5775 Morehouse Dri- (21) ve, San Diego, California 92121-1714 (US). LIU, Chih- International Application Number: Hao; c/o QUALCOMM INCORPORATED, 5775 More- PCT/US2017/058824 house Drive, San Diego, California 92121-1714 (US). PA- (22) International Filing Date: TEL, Chirag; c/o QUALCOMM INCORPORATED, 5775 27 October 2017 (27.10.2017) Morehouse Drive, San Diego, California 92121-1714 (US). RICO ALVARINO, Alberto; c/o QUALCOMM INCOR- (25) Filing Language: English PORATED, 5775 Morehouse Drive, San Diego, California (26) Publication Language: English 92121-1714 (US). (30) Priority Data: (74) Agent: HODGES, Jonas J. et al.; c/o ARENT FOX LLP, 62/416,651 02 November 2016 (02.11.2016) US 1717 K Street NW, Washington, District of Columbia 15/635,018 27 June 2017 (27.06.2017) US 20006-5344 (US). (71) Applicant: QUALCOMM INCORPORATED [US/US]; (81) Designated States (unless otherwise indicated, for every ATTEN: International IP Administration, 5775 Morehouse kind of national protection available): AE, AG, AL, AM, Drive, San Diego, California, US 92121-1714 (US). AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (72) Inventors: YERRAMALLI, Srinivas; c/o QUALCOMM DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, INCORPORATED, 5775 Morehouse Drive, San Diego, (54) Title: WIRELESS COMMUNICATION BETWEEN WIDEBAND ENB AND NARROWBAND UE = = 1000 = = U L transmission unit _ ... ... — _ ....-• ....... .... ... ... ... ... .... .... .. ... 1002 1004 ---. ...-- ...... , , ..... r _. = I UE1 :5 ms ON period UE1 :5 ms OFF period = 1006 \ 1008 ri UE1 on, UE 2 off UE1 off,UE2 on = = = = = FIG. 10 ,-1 (57) : A method and apparatus for wireless communication in the unlicensed spectrum between an eNB and UEs having CN different bandwidths, e.g., between a narrowband UE and a wideband eNB. A user equipment apparatus segments an uplink duration in 71' , 1 each frame into multiple transmission units for each frequency, wherein a frame comprises an integer number of the transmission units. In The apparatus transmits uplink communication based on the multiple transmission units, wherein each transmission unit comprises at °O least one on period and at least one off period corresponding to each of a plurality of frequencies, wherein during an on period the 0 —. UE transmits uplink communication on the corresponding frequency and during an off period the UE refrains from transmitting uplink *1: communication on the corresponding frequency. Each transmission unit may comprise multiple on periods and multiple off periods. 1-1 c;;;;) The on/off periods may be configured by a base station or specified for each frame type. ei O [Continued on next page] WO 2018/085149 Al MIDEDIMOMOIDEIREIDIONIMHEMOEHHOMOVOIMIE HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

WIRELESS COMMUNICATION BETWEEN WIDEBAND ENB AND NARROWBAND UE

52280328_US

68937361_US,71809032_US,71919680_US,56324952_US,71212601_US

H04B 1/713,H04L 1/12,H04L 1/189,H04L 5/001,H04L 5/0012,H04L 5/0023,H04L 5/0048,H04L 5/14,H04L 67/12,H04W 4/70,H04W 16/14,H04W 28/26,H04W 72/0413,H04W 72/042,H04W 72/0446,H04W 72/0453,H04W 72/048,H04W 72/1289,H04W 74/004,H04W 74/0808,H04W 88/02,H04W 88/08

2013-05-17

N

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/173761 A2 (51) International Patent Classification: C07K16/24 (2006.01) C12N15/11 (2006.01) (21) International Application Number: PCT/US2013/041656 (22) International Filing Date: 17 May 2013 (17.05.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/649,147 18 May 2012 (18.05.2012) US 61/792,619 15 March 2013 (15.03.2013) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). (72) Inventors: SMITH, Dirk E.; 11633 Meadowmeer Circle NE, Bainbridge Island, Washington 98110 (US). FOLTZ, Ian; 2108 Knightswood Place, Burnaby, BC V5A 4B9 (CA). KING, Chadwick T.; 1325 Moody Avenue, North Vancouver, BC V7L 3T5 (CA). LIM, Ai Ching; 7105 82nd Avenue SE, Mercer Island, Washington 98040 (US). CLARK, Rutilio; 5335 Old Mill Road NE, Bainbridge Is­ land, Washington 98110 (US). COMEAU, Michael R.; 1044 High School Road NE, Bainbridge Island, Washing­ ton 98110 (US). KETCHEM, Randal R.; 6332 152nd Street SE, Snohomish, Washington 98296 (US). SHI, Donghui; 3198 Rickey Court, Thousand Oaks, California 91362 (US). MIN, Xiaoshan; 2108 Clarice Lane, Burl- ingame, California 94010 (US). WANG, Zhulun; 660 Glenbrook Drive, Palo Alto, California 94306 (US). (74) Agent: WRONA, Thomas J.; Amgen Inc., 1201 Amgen Court W¿ Seattle, Washington 98119-3105 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, ¿ [Continued on next page] (54) Title: ST2 ANTIGEN BINDING PROTEINS < 1 \' P FIG. 8 i-H o CJ (57) Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, includ - © ing antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflam­ matory disorders. WO 2013/173761 A2 I lllll llllllll II llllll III lllll lllll III III III lllll llll llll lllll lllll lllll lllll lllllll llll llll TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: ¿ as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) ¿ as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: ¿ without international search report and to be republished upon receipt of that report (Rule 48.2(g)) ¿ with sequence listing part of description (Rule 5.2(a))Se describen en la presente composiciones y métodos relacionados con proteínas de unión a antígeno que se unen al receptor ST2 humano, incluyendo anticuerpos. En modalidades particulares, la divulgación provee anticuerpos completos dirigidos contra ST2 humano, y derivados y variantes de los mismos. Además se proveen ácidos nucleicos que codifican dichos anticuerpos y fragmentos de anticuerpo, variantes, y derivados. También se proveen métodos para elaborar y usar dichos anticuerpos, incluidos métodos para tratar y prevenir trastornos autoinmunitarios e inflamatorios.

en

ST2 ANTIGEN BINDING PROTEINS

6179688_US

12598550_US,50238826_CN,16665820_US,12598668_US,12708752_US,46535138_US,73554509_US,12583091_CA,16796181_CA,46862565_US

A61K 39/44,A61K2039/505,A61P 1/04,A61P 7/00,A61P 9/00,A61P 11/00,A61P 11/02,A61P 11/06,A61P 17/00,A61P 17/02,A61P 19/02,A61P 19/08,A61P 25/00,A61P 27/16,A61P 29/00,A61P 31/04,A61P 31/18,A61P 35/00,A61P 37/00,A61P 37/02,A61P 37/06,A61P 37/08,A61P 43/00,C07K 16/24,C07K 16/244,C07K 16/28,C07K 16/2866,C07K2317/21,C07K2317/33,C07K2317/34,C07K2317/51,C07K2317/515,C07K2317/56,C07K2317/565,C07K2317/76,C07K2317/92,C12N 15/11,C12N 15/63,Y10S 530/809

2018-01-11

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 July 2018 (19.07.2018) WI PO I PCT Hu omit VIII OH olo offinionimoilowo Hs (10) International Publication Number WO 2018/132590 Al 101 102 103 (51) International Patent Classification: GOOK 9 / 2 0 (2006.01) GOOK 9 / 8 0 (2006.01) GOOK 9 / 4 6 (2006.01) GOOF 17/18 (2006.01) (21) International Application Number: PCT/US2018/013344 (22) International Filing Date: 11 January 2018 (11.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201710018395.1 11 January 2017 (11.01.2017) CN 15/864,572 08 January 2018 (08.01.2018) US (71) Applicant: ALIBABA GROUP HOLDING LIMITED [ /US]; Fourth Floor, One Capital Place, P.O. Box 847, George Town (KY). (72) Inventors: WANG, Linqing; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No.18 Wantang Road, Hangzhou, 310099 (CN). ZENG, Xiaodong; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No.18 Wantang Road, Hangzhou, 310099 (CN). ZHANG, Hong; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No.18 Wantang Road, Hangzhou, 310099 (CN). LIN, Feng; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No.18 Wantang Road, Hangzhou, 310099 (CN). (74) Agent: STALFORD, Terry, J.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (54) Title: IMAGE RECOGNITION METHOD AND APPARATUS BASED ON AUGMENTED REALITY Gather user information uploaded by an augmented reality client terminal v Screen out picture feature samples associated with the user information from a preset picture feature sample library • Generate, on the basis of the screened-out picture feature samples, a picture feature sample sub-library corresponding to the user information, and push the picture feature sample sub-library to the augmented reality client terminal, so that during image scanning in an offline environment of a user, the AR client terminal performs image recognition on the scanned image information on the basis of the picture feature sample sub-library FIG. 1 O (57) : The present application provides an image recognition method based on augmented reality, which includes: gathering user information uploaded by an augmented reality client terminal; screening out picture feature samples associated with the user information from a preset picture feature sample library; and generating, on the basis of the screened-out picture feature samples, a picture feature sample sub-library corresponding to the user information, and pushing the picture feature sample sub- library to the augmented reality client terminal, so that during image scanning in an offline environment of the user, the augmented reality client 00 terminal performs image recognition on the scanned image information on the basis of the picture feature sample sub-library. The O present application can improve the image recognition efficiency of an AR client terminal. C [Continued on next page] WO 2018/132590 Al MIDEDIMOMOIDEIREEMOMOMMOHINEOMMEHOIS KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

IMAGE RECOGNITION METHOD AND APPARATUS BASED ON AUGMENTED REALITY

11236634_

56332459_CN,72014544_CN,74287629_CN,67857500_CN

G06F 16/5838,G06T 11/60,G06T 19/006,G06V 10/44,G06V 10/751,G06V 20/20,G06V 20/30,H04L 67/131,H04L 67/53,H04L 67/535,H04L 67/55

2018-02-09

N

W O 20 18/ 175 0 12 Al FIG. 24 2410 ( -2412 Generate, based on the compadson, missing target samples using at least one of a reform= frame based on the reference channel or a target frame based on the modified newt channel. where the fins, signal corresponds to a portion lithe reference frame, and where the second signal ourresponds to a portion of the target frame. ( 2408 Determine a temporal correlertion value indicative of a tempond ourrelertion between a fina signal associated with the referemx channel and a wound signal associated with the modified target channel ( .2404 Identify a target channel and a .eference channel, the target channel and the reference channel identified film the two or more channels based on a mismatch value ( 2406 Caleraa a modified Ursa channel by tempondly adjusting the target channel bawd on the mismatch value. the mismatch value indicative of an amount of tumoral mismatch between the target channel and the reference channel Compare the tniaporill corre (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT ill mu °mons I SID o olommoollm VIII VII VII IE (10) International Publication Number WO 2018/175012 Al (51) International Patent Classification: G10L 19/008 (2013.01) (21) International Application Number: PCT/US2018/017654 (22) International Filing Date: 09 February 2018 (09.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/474,010 20 March 2017 (20.03.2017) US 15/892,130 08 February 2018 (08.02.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: ATTI, Venkatraman; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). CHEBIYYAM, Venkata Subrahmanyam Chandra Sekhar; 5775 More- house Drive, San Diego, California 92121-1714 (US). (74) Agent: TOLER LAW GROUP, PC et al.; 8500 Bluffstone Cove, Suite A201, Austin, Texas 78759 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: TARGET SAMPLE GENERATION (57) : A method of encoding audio channels includes receiving two or more channels at an encoder and identifying a target channel and a reference channel. The target channel and the reference channel are identified from the two or more channels based on a mismatch value. The method also includes generating a modified target channel by temporally adjusting the target channel based on the mismatch value. The mismatch value is indicative of an amount of temporal mismatch between the target channel and the reference channel. The method also includes determining a temporal correlation value indicative of a temporal correlation between a first signal associated with the reference channel and a second signal associated with the modified target channel. The method also includes comparing the temporal correlation value to a threshold. The method further includes generating missing target samples based on the comparison, a coder type, or both.

en

TARGET SAMPLE GENERATION

52280328_US

71175944_US,71203048_US

G10L 19/005,G10L 19/008,G10L 19/12,H04S 3/008,H04S2400/03,H04S2400/15

2018-01-12

N

Singleprocessor Vision Sensor System 1350 Queries Peripheral Circuitry —0 1370 Dedicated Processor 1312 1314 r- 1 1340 Visual Sensor Array Unit Face Detection Event A 1330 4 0 1372 1374 110 Device Controller Memory CV Hardware Controller Core Application Processor Core Visual Input FIG. 13B 1-1 00 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT omit VIII °nolo 10110111 OH oimIE (10) International Publication Number WO 2018/136325 Al (51) International Patent Classification: GOOK 9/00 (2006.01) GOOK 9 / 5 6 (2006.01) GOOK 9 / 4 6 (2006.01) (21) International Application Number: PCT/US2018/013501 (22) International Filing Date: 12 January 2018 (12.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/413,390 23 January 2017 (23.01.2017) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: GOUSEV, Evgeni; 5775 Morehouse Dri- ve, San Diego, California 92121-1714 (US). GOVIL, Alok; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). MAITAN, Jacek; 5775 Morehouse Dri- ve, San Diego, California 92121-1714 (US). RASQUIN- HA, Nelson; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). RANGAN, Venkat; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). PARK, Ed- win Chongwoo; 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). (74) Agent: CHANG, Ko-Fang et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, N.E., Suite 2800, Atlanta, Georgia 30309 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (54) Title: SINGLE-PROCESSOR COMPUTER VISION HARDWARE CONTROL AND APPLICATION EXECUTION (57) : Apparatuses, methods, and systems are presented for reacting to scene-based occurrences. Such an apparatus may comprise dedicated computer vision (CV) computation hardware configured to receive sensor data from a sensor array comprising a plurality of sensor pixels and capable of computing one or more CV features using readings from neighboring sensor pixels of the sensor array. The apparatus may further comprise a first processing unit configured to control operation of the dedicated CV computation hardware. The first processing unit may be further configured to execute one or more application programs and, in conjunction with execution of the one or more application programs, communicate with at least one input/output (I/O) device controller, to effectuate an I/O operation in reaction to an event generated based on operations performed on the one or more computed CV features. [Continued on next page] WO 2018/136325 Al MIDEDIMOMOIDEIREEMOMMIMIMMOHOMEHOIS DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))

en

SINGLE-PROCESSOR COMPUTER VISION HARDWARE CONTROL AND APPLICATION EXECUTION

52280328_US

74321839_US,74403541_US,74057320_US,73481778_US,74055909_US,73901086_US

G06V 10/36,G06V 10/50,G06V 10/955,G06V 20/44,G06V 40/107,G06V 40/16

2018-04-19

N

FirstLoudspeaker Second Output Channel 128 Second Loudspeaker 144 First Audio Channel 130 (\'Reference Channel\') Second Audio Channel 132 (Target Channel\') Second Microphone 148 First Microphone 146 Modified Non Harmonic HB Flag (y) 920 Down-Mix Bitstream 216 ICBWE Bitstream 242 High-Band Mid Channel Bitstream 244 Low-Band Bitstream 246 Modified Non Harmonic FIB Flag (y) 920 Down-Mix Bitstream 216 ICBWE Bitstream 242 High-Band Mid Channel Bitstream 244 Low-Band Bitstream 246 100 First Output Channel 126 First Device 104 Memory 153 Instructions 191 Transmitter 110 Input I nterface(s) 112 Encoder 200 Inter-Channel BWE Encoder 204 Non Harmonic HB Flag (x) 910 Modified Non Harmonic HB Flag (y) 920 ( 106 Second Device Decoder 300 I ICBWE Decoder 306 I Modified Non Harmonic HB Flag (y) 920 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT ill IIIIIl °million °nolo mu imm Eno iflo oimIE (10) International Publication Number WO 2018/195299 Al (51) International Patent Classification: G1OL 19/008 (2013.01) G1OL 21/038 (2013.01) G1OL 19/02 (2013.01) (21) International Application Number: PCT/US2018/028338 (22) International Filing Date: 19 April 2018 (19.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/488,654 21 April 2017 (21.04.2017) US 15/956,645 18 April 2018 (18.04.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: CHEBIYYAM, Venkata Subrahmanyam Chandra Sekhar; 590 Mill Creek Lane, #205, Santa Clara, California 95054 (US). ATTI, Venkatraman; 5775 More- house Drive, San Diego, California 92121-1714 (US). (74) Agent: TOLER LAW GROUP, PC et al.; 8500 Bluffstone Cove, Suite A201, Austin, Texas 78759 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (54) Title: NON-HARMONIC SPEECH DETECTION AND BANDWIDTH EXTENSION IN A MULTI-SOURCE ENVIRON- = MENT FIG. 1 M Sound Source152 (57) : A device includes a multi-channel encoder configured to receive a first audio signal and a second audio signal, to perform a downmix operation on the first audio signal and the second audio signal to generate a mid signal, to generate a low-band mid signal and a high-band mid signal based on the mid signal, and to determine, based at least partially on a low band voicing value corresponding to the low band signal and a gain value corresponding to the high-band mid signal, a value of a multi-source flag that 00 flag associated with the high-band mid signal. The multi-channel encoder is configured to generate a high-band mid excitation signal O based on the multi-source flag and to generate a bitstream based on the high-band mid excitation signal. The device also includes a transmitter configured to transmit the bitstream and the multi-source flag to a second device. C [Continued on next page] WO 2018/195299 Al OII (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

NON-HARMONIC SPEECH DETECTION AND BANDWIDTH EXTENSION IN A MULTI-SOURCE ENVIRONMENT

52280328_US

71203048_US,71175944_US

G10L 19/008,G10L 19/0204,G10L 21/038,G10L 21/0388

2017-11-03

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\' WO 2018/128691 Al 12 July 2018 (12.07.2018) WIP0 1 PCT (51) International Patent Classification: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A01K 67/027 (2006.01) C12N 15/85 (2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, C12N 15/90 (2006.01) CO7K 16/00 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: (84) Designated States (unless otherwise indicated, for every PCT/US2017/060006 kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 03 November 2017 (03.11.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (25) Filing Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (30) Priority Data: KM, ML, MR, NE, SN, TD, TG). 62/417,845 04 November 2016 (04.11.2016) US 62/567,932 04 October 2017 (04.10.2017) US Declarations under Rule 4.17: — (71) Applicant: REGENERON PHARMACEUTICALS, of inventorship (Rule 4.17(iv)) INC. [US/US]; 777 Old Saw Mill Rover Road, Tarrytown, Published: NY 10591-6706 (US). — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (72) Inventors: GUO, Chunguang; c/o Regeneron Pharmaceu- claims and to be republished in the event of receipt of ticals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY amendments (Rule 48.2(h)) 10591 (US). HARRIS, Faith; c/o Regeneron Pharmaceuti- cals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY = 10591 (US). VORONINA, Vera; c/o Regeneron Pharma- _ ceuticals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY 10591 (US). MCWHIRTER, John; c/o Regeneron =_ — Pharmaceuticals, Inc., 777 Old Saw Mill Rover Road, Tar- rytown, NY 10591 (US). LEVENKONA, Natasha; c/o Re- generon Pharmaceuticals, Inc., 777 Old Saw Mill Rover = Road, Tarrytown, NY 10591 (US). MACDONALD, Lynn; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY 10591 (US). TU, Naxin; c/o = _ Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Rover = Road, Tarrytown, NY 10591 (US). MURPHY, Andrew, _ J.; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill = = Rover Road, Tarrytown, NY 10591 (US). Agent: SCHONEWALD, Stephanie, L.; Choate, Hall & (74) Stewart LLP, Two International Place, Boston, MA 02110 = (US). = (81) Designated States (unless otherwise indicated, for every — kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = — 1-1 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Il ON (54) Title: NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN LOCUS GO (57) : Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non- e\'' human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). 1-1 —. Non-human animals described herein express antibodies that contain human Igk light chains, in whole or in part. In particular, non- GO human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Ig?. light 1-1 © chains, in whole or in part, that are encoded by human Igk light chain-encoding sequences inserted into an endogenous Igk light chain f'1 locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided. 0

en

NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN LOCUS

55538596_US

71251733_US,71179821_US,55118631_US,71328346_US,56532202_US,55461541_US,57330592_US,71897378_US

A01K 67/0278,A01K2207/15,A01K2217/05,A01K2217/072,A01K2217/075,A01K2227/105,A01K2267/01,C07K 16/00,C07K2317/14,C07K2317/24,C12N 15/907,C12N2015/8518,C12N2800/30

2018-03-23

N

subfame n F 1 SF PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH 922 924 926 928 930 932 934 936 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT ill mu °mons I SID o VIII SID Hiolom No VII IE (10) International Publication Number WO 2018/175822 Al (51) International Patent Classification: HO4W 72/02 (2009.01) H04 TY 72/10 (2009.01) H04 TY 72/06 (2009.01) H04 TY 84/18 (2009.01) (21) International Application Number: PCT/US2018/023911 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/476,330 24 March 2017 (24.03.2017) US 15/928,652 22 March 2018 (22.03.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; Attn: International IP Administration, 5775 Morehouse Dri- ve, San Diego, CA 92121-1714 (US). (72) Inventors: GULATI, Kapil; 5775 Morehouse Drive, San Diego, CA 92121 (US). NGUYEN, Tien Viet; 5775 More- house Drive, San Diego, CA 92121 (US). BAGHEL, Sud- hir Kumar; 5775 Morehouse Drive, San Diego, CA 92121 (US). WU, Zhibin; 5775 Morehouse Drive, San Diego, CA 92121 (US). PATIL, Shailesh; 5775 Morehouse Drive, San Diego, CA 92121 (US). (74) Agent: TEMPEL, Michael, J. et al.; Smith Tempel Blaha LLC, 50 Glenlake Parkway, Suite 340, Atlanta, GA 30328 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (54) Title: LOW LATENCY ENHANCEMENTS TO CV2X AUTONOMOUS RESOURCE SELECTION AND RE-SELECTION PROCEDURE FOR VEHICLE-TO-VEHICLE COMMUNICATIONS Freq 1 SF 1 SF 900 940 942 944 946 PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH — PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH 00 N 00 O O 938- ) T2 ( -901 =Candidate resources for 910 resource (re)selection (set S B ) Candidate resources without exclusions FIG. 9 (57) : Low latency enhancements for communication systems, including autonomous driving and/or selection scenarios, are provided. A method for communication includes monitoring communication resources in a communication system, determining a set of candidate resources to use for subsequent transmission of information within a time window such that the time window is minimized based on a desired communication latency parameter that considers at least one or more of communication channel congestion and a priority of transmission, determining a set of lowest energy resources from the set of candidate resources, selecting a low energy resource from the set of lowest energy resources, and transmitting data on the selected low energy resource. Other aspects, embodiments, and features are also claimed and described. [Continued on next page] Time WO 2018/175822 Al MIDEDIMOMMIDIREEM3111111111111111111111111111111111111111111111111 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

LOW LATENCY ENHANCEMENTS TO CV2X AUTONOMOUS RESOURCE SELECTION AND RE-SELECTION PROCEDURE FOR VEHICLE-TO-VEHICLE COMMUNICATIONS

52280328_US

74264305_US,73968545_US,71931965_US,73488171_US,74004761_US

H04B 17/382,H04L 5/006,H04L 5/0064,H04L 5/0071,H04W 4/40,H04W 4/44,H04W 4/46,H04W 24/02,H04W 24/08,H04W 28/021,H04W 72/02,H04W 72/044,H04W 72/06,H04W 72/10,H04W 76/14,H04W 84/005,H04W 84/18,H04W 88/06,H04W 92/10

2018-03-22

N

PSSPit-t-tt PBCH Bandwidth/ Third Bandwidth Time Self- Decodable F rst Portion of Bandwidth PBCH 425; Second Bandwidth Frequency Sync Signal Frequency 430 SSS 410 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT ill mu °million °nolo Oil mo Ho oimIE (10) International Publication Number WO 2018/194790 Al (51) International Patent Classification: HO4L 1/00 (2006.01) H04L 5/00 (2006.01) (21) International Application Number: PCT/US2018/023835 (22) International Filing Date: 22 March 2018 (22.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/488,637 21 April 2017 (21.04.2017) US 62/564,030 27 September 2017 (27.09.2017) US 15/877,976 23 January 2018 (23.01.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: LY, Hung; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). JIANG, Jing; 5775 More- house Drive, San Diego, California 92121-1714 (US). RI- CO ALVARINO, Alberto; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). WANG, Xiao Feng; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). LUO, Tao; 5775 Morehouse Drive, San Diego, Cal- ifornia 92121-1714 (US). SORIAGA, Joseph, Binamira; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). SARKIS, Gabi; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: ANDERSON, Thomas D.; Holland & Hart LLP, P.O. Box 11583, Salt Lake City, Utah 84147 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: TECHNIQUES TO ENCODE OR DECODE A SELF-DECODABLE PORTION OF A PHYSICAL BROADCAST CHAN- NEL IN A SYNCHRONIZATION SIGNAL BLOCK (57) : Techniques for wireless communication are de- scribed. A method of wireless communication at a user equip- ment (UE) includes receiving a synchronization signal within a synchronization signal (SS) block; receiving at least a portion of a physical broadcast channel (PBCH) of the SS block, the PBCH comprising a self-decodable portion and an outside portion; and decoding the PBCH based at least in part on receiving the self- decodable portion of the PBCH. The synchronization signal has a first bandwidth. The self-decodable portion of the PBCH has a second bandwidth substantially within the first bandwidth. The outside portion having a bandwidth that is outside of the second bandwidth and within a PBCH bandwidth, the PBCH bandwidth being greater than the first bandwidth. W O 20 18/ 19 47 90 Al 415 ---r..7771 PBCH 420 DMR S FIG. 4 400 [Continued on next page] WO 2018/194790 Al MIDEDIMOMMIONE101301ROMOIROMMEM# TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))

en

TECHNIQUES TO ENCODE OR DECODE A SELF-DECODABLE PORTION OF A PHYSICAL BROADCAST CHANNEL IN A SYNCHRONIZATION SIGNAL BLOCK

52280328_US

69248658_US,65672214_US,56543372_US,73946143_US,68937361_US,56459191_US,67553613_US

H04L 1/0009,H04L 1/0045,H04L 1/0057,H04L 1/0071,H04L 1/04,H04L 1/08,H04L 5/005,H04L 5/0053,H04W 56/001,H04W 88/02,H04W 88/08

2018-05-03

N

Determinea channel format for transmitting uplink communications in a slot, where the channel format is based on at least a payload size r Determine whether intra-slot frequency hopping is configured „... 402 404 W O 20 18/ 20 4666 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIP0 I PCT 0111111010 0111 °nolo HoloimilmoilioluovoimIE (10) International Publication Number WO 2018/204666 Al (51) International Patent Classification: H04L 5/00 (2006.01) (21) International Application Number: PCT/US2018/030916 (22) International Filing Date: 03 May 2018 (03.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/502,421 05 May 2017 (05.05.2017) US 15/969,477 02 May 2018 (02.05.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: WANG, Renqiu; c/o QUALCOMM INCOR- PORATED, 5775 Morehouse Drive, San Diego, Califor- nia 92121-1714 (US). HUANG, Yi; c/o QUALCOMM IN- CORPORATED, 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). XU, Hao; c/o QUALCOMM IN- CORPORATED, 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). GAAL, Peter; c/o QUALCOMM INCORPORATED, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: BINDSEIL, James J. et al.; c/o ARENT FOX LLP, 1717 K Street NW, Washington, District of Columbia 20006-5344 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: CHANNEL FORMATS WITH FLEXIBLE DURATION IN WIRELESS COMMUNICATIONS (57) : Aspects herein describe determining a channel format for transmitting uplink communications in a slot, wherein the channel format is selected from multiple channel formats based at least in part on a payload size of the uplink communications, determining a starting symbol and an ending symbol of an uplink channel duration of the slot for transmitting the uplink communications, determining, based at least in part on the starting symbol and the ending symbol, a portion of the channel format to utilize in transmitting the uplink communications in the slot, and transmitting the uplink com- munications in the slot, wherein transmitting the uplink communications is based on the portion of the channel format. Determine a starting symbol and an ending symbol of an uplink channel duration of the slot Determine, based at lent in part on the starting symbol and the ending symbol, a portion of the channel format to utilize k nansmitting the uplink communications rldetermine a user multiplewng scheme. I 410 I spreading factor, or orthogonal cover I set based on the channel format Transmit the uplink communications in the slot based on the portion aloe channel format , ,412 FIG. 4 [Continued on next page] / 408 WO 2018/204666 Al MIDEDIMOMMIDIRE101001010IMEHROMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

CHANNEL FORMATS WITH FLEXIBLE DURATION IN WIRELESS COMMUNICATIONS

52280328_US

56570006_US,69235791_US,56286106_US,71547434_US

H04B 1/713,H04J 13/16,H04J2013/165,H04L 5/0007,H04L 5/001,H04L 5/0012,H04L 5/0016,H04L 5/0023,H04L 5/0042,H04L 5/0044,H04L 5/0048,H04L 5/0092,H04L 5/1469,H04W 72/044,H04W 72/1268

2017-10-26

N

artCy {in CDR) y-region mAb constant region peptide---N () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIP0 I PCT omit °nolo omm im °mono lio iflo oimIE (10) International Publication Number WO 2018/081370 Al (51) International Patent Classification: C07K 14/47 (2006.01) A61K 38/04 (2006.01) (21) International Application Number: PCT/US2017/058455 (22) International Filing Date: 26 October 2017 (26.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/413,586 27 October 2016 (27.10.2016) US 62/413,613 27 October 2016 (27.10.2016) US (71) Applicant: JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventor; and (71) Applicant (for US only): MACIELAG, Mark [US/US]; 1400 McKean Road, Spring House, PA 19477 (US). (72) Inventors: MACIELAG, Mark; 1400 McKean Road, Spring House, PA 19477 (US). PATCH, Raymond, J.; 1400 McKean Road, Spring House, PA 19477 (US). ZHANG, Rui; 1400 McKean Road, Spring House, PA 19477 (US). CASE, Martin, A.; 3210 Merryfield Row, San Diego, CA 92121 (US). RANGWALA, Shamina, M.; 1400 McKean Road, Spring House, PA 19477 (US). LEONARD, James, N.; 1400 McKean Road, Spring House, PA 19477 (US). CAMACHO, Raul, C.; 1400 McKean Road, Spring House, PA 19477 (US). HUNTER, Michael, J.; 3210 Merryfield Row, San Diego, CA 92121 (US). D'AQUINO, Katharine, E.; 1400 McKean Road, Spring House, PA 19477 (US). EDWARDS, Wilson; 3210 Merryfield Row, San Diego, CA 92121 (US). SWANSON, Ronald, V.; 3210 Merryfield Row, San Diego, CA 92121 (US). MAN, Wenying; 1400 McKean Road, Spring House, PA 19477 (US). ZHANG, Yue-Mei; 1400 McKean Road, Spring House, PA 19477 (US). WALL, Mark; 1400 McK- ean Road, Spring House, PA 19477 (US). CHI, Ellen; 3210 Merryfield Row, San Diego, CA 92121 (US). (74) Agent: BARANIAK, Andrew, P. et al.; Panitch Schwarze Belisario & Nadel LLP, Two Commerce Square, 2001 Mar- ket Street, Suite 2800, Philadelphia, PA 19103 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) = (54) Title: ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEU- = ROPEPTIDE Y RECEPTORS Fig. I O (57) : The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. \' The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, C treating or ameliorating diseases and disorders disclosed herein. [Continued on next page] 1-1 O N 1-1 00 WO 2018/081370 Al MIDEDIMOHNOIREIEREIMMENHOMMEHOIS Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))

en

ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS

55088190_BE

71951748_US,71305223_US,71810478_US,71885247_US,71647517_US,71892891_US,71203025_US,71543903_US,65137180_US,71955525_US,69230829_US,71691104_US,71691104_US,71302727_US,71328251_US,72024167_US

A61K 9/0019,A61K 38/00,A61K 38/17,A61K 38/1709,A61K 38/22,A61K 38/26,A61K 45/06,A61K 47/542,A61K 47/60,A61K 47/64,A61K 47/68,A61K 47/6811,A61K 47/6845,A61K 47/6883,A61K 47/6889,A61K 49/0032,A61K 49/0052,A61K 49/0056,A61K2039/505,A61P 3/00,A61P 3/04,A61P 3/06,A61P 3/08,A61P 3/10,C07K 1/061,C07K 1/1072,C07K 1/12,C07K 1/18,C07K 5/0205,C07K 14/575,C07K 14/57545,C07K 16/00,C07K 16/24,C07K2317/14,C07K2317/21,C07K2317/24,C07K2317/33,C07K2317/52,C07K2317/55,C07K2317/56,C07K2317/565,C07K2317/567,C07K2317/71,C07K2317/92,C07K2317/94,C07K2319/30

2018-04-25

Y

This system is used to rejuvenate youth by targeting the pituitary gland to produce HGH and testosterone. Also, with this system, a personal avatar is created, so that a person with the help of virtual reality, optional, simulate traveling to a specific brain site and giving a stimulation to that site. Also, the personal avatar will travel inside a designated vehicle type for that purpose. Also, The Smart Brain System is a type of a platform that can work with all brain stimulation products. It should become the model that people will use for brain control via the internet. Using this system, the brain is re-wired or re-programmed as to where a stimulation is received within the brain. A person will view a simulation of an electrical stimulation current that transmits to an area of the brain they desire to stimulate. Watching the smart brain simulations enables the mind to have a visual perception of the area of the brain to stimulate. So that by using the mind, vision and sense of hearing and touch, we can show the brain where a stimulation should be received within the brain. Also, using this system will allow the individual to have a more personal role in their brain stimulation therapy. This system can be used in clinical and office settings, although it is primarily for use via the internet. The smart brain system can be produced for use in all languages and marketed to all countries via the internet. The person will log into the smart brain web site. They will be asked to purchase the E-transporter system. It consists of a USB cable that has rectangular panels along its length. These panels are lights, which are programmed to indicate the direction of a current or movement of an object or stimulus within the cable. It will attach at the hand and continue up the arm and onto the back of the neck. Electrode wires with pads branch out at the neck to be placed on the head. This E-transporter and controller have a vibrational capacity, an electrical stimulation capacity, a speech and speech recognition capacity, and a sound effect capacity. It plugs into the computer at the USB port. The user will upload a photo of them self, preferably while wearing the E-transporter, to the web sites database. (This step is optional since a generic photo and E-transporter system can be used). A pre-programmed format will graft a computerized version of the brain into their photo. The therapist or individual will impute the type of brain stimulation they want to generate. When prompted, the program will display a cut-out view of their head displaying the computerized brain inside. When prompted, a pre-programmed video displays a simulated current that transmits to the target region of the brain to be stimulated. When the simulated current enters the target region of the brain, signs and signals will be displayed indicating that the area is being stimulated or that a downloading is in progress. The E-transporter lighting effects, vibrations and tactile properties will work simultaneously with the copy of the E-transporter and simulations that are displayed on the screen. The E-transporter wearable unit and the personal photo enhances the biofeedback that the simulated stimulations are occurring in the individual's own brain. Different concepts of brain design and brain activities can be used. One example would be: simulating the brain as an electronic component and displaying its electronic properties as brain activities. Another example is: simulating the brain as having caves and having a tunnel system that the stimulus travels through etc. The smart brain web site and E-transporter system will be produced by neuroscientists, medical illustrators, computer programmers, video production programmers, graphic designers, business developers, patent attorneys, and many others. Clinical trials are still needed to prove that this type of visual and neuronal feedback is an effective tool for brain stimulation therapy and that it adds a real benefit to brain stimulation therapy that is already being done.

en

Device and method for localization of brain function related applications

58021426_US

58021426_US

A61B 5/375,A61B 5/378,A61B 5/38,A61B 5/4064,A61M 21/00,A61M2021/0072,G06F 3/015,G06T 13/00,G16B 5/00,G16H 50/50

2018-04-27

N

APCOR TUMOR CELL APC OR TUMOR CELL REINVIGORATED T CELL CYTOKINES EFFECTOR MECHANISMS INHIBITORY aTIM- ACTIVATION SIGNAL SIGNAL PD-1 LAG-3 TCR )ritAG-3 aPD-1 EXHAUSTED T CELL ACTIVATION SIGNAL TCR Ag MHC TIM-3 Ag MHC (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT omit VIII °nolo Holollm olo lionoiliflo oimIE (10) International Publication Number WO 2018/201096 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/030027 (22) International Filing Date: 27 April 2018 (27.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/491,221 27 April 2017 (27.04.2017) US 62/578,215 27 October 2017 (27.10.2017) US 62/614,998 08 January 2018 (08.01.2018) US 62/625,276 01 February 2018 (01.02.2018) US 62/657,384 13 April 2018 (13.04.2018) US (71) Applicants: TESARO, INC. [US/US]; 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). ANAP- TYSBIO, INC. [US/US]; 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). (72) Inventors: JUN, Helen, Toni; c/o Anaptysbio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). KEHRY, Marilyn; c/o Anaptysbio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). BOWERS, Peter; c/o Anaptysbio, Inc., 10421 Pa- cific Center Court, Suite 200, San Diego, CA 92121 (US). KING, David, J.; c/o Anaptysbio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). BOBILEV, Dmitri; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). GHOSH, Srimoyee; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). HUANG, Baochuan; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). JENKINS, David; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). (74) Agent: ESPINO, Christine, G. et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US). (54) Title: ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THERE- OF FIGURE 1 1-1 01 O O 1-1 (57) : The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided 0 are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is \' responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease. C [Continued on next page] WO 2018/201096 Al MIDEDIMOMOIDEIRDERI00101011M0101101EIMOVOIMIE (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))

en

ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF

71731222_US,56534361_US

73787348_US,56490901_US,73470684_US,71726370_US,71259870_US,56431054_US,71003247_US,74264596_US

A61K 39/3955,A61K 45/06,A61K2039/505,A61K2039/507,A61K2039/54,A61K2039/545,A61P 35/00,C07K 16/2803,C07K 16/2818,C07K2317/41,C07K2317/70,C07K2317/76,C07K2317/92,Y02A 50/30

2018-03-13

N

WO 18/ 169989 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT ill~~~~~~~~ 011101VIIIVIIIVIII olo VIII VIII omom oimIE (10) International Publication Number WO 2018/169989 Al (51) International Patent Classification: H04N 19/00 (2014.01) (21) International Application Number: PCT/US2018/022226 (22) International Filing Date: 13 March 2018 (13.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/470,809 13 March 2017 (13.03.2017) US 15/919,060 12 March 2018 (12.03.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: CHUANG, Hsiao-Chiang; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). CHEN, Jianle; 10756 Corte De Tiburon, San Diego, California 92130 (US). CHEN, Yi-Wen; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). LI, Xiang; 10574 Gaylemont Lane, San Diego, California 92130 (US). KAR- CZEWICZ, Marta; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). CHIEN, Wei-Jung; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: JOSEPH, Jeffrey R.; Shumaker & Sieffert, PA., 1625 Radio Drive, Suite 100, Woodbury, Minnesota 55125 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: INTER PREDICTION REFINEMENT BASED ON BI-DIRECTIONAL OPTICAL FLOW (BIO) (57) : A video decoder can be configured to determine that a 220 block of video data is encoded using a bi-directional inter prediction A ,-- --- mode; determine that the block of video data is encoded using a bi-direc- tional optical flow (BIO) process; inter predict the block of video data according to the bi-directional inter prediction mode; perform the BIO • 2 22 process for the block, wherein performing the BIO process for the block comprises determining a single motion vector refinement for a group of pixels in the block, wherein the group of pixels comprises at least two pixels; refine the group of pixels based on the single motion vector refine- ment; and output a BIO refmed predictive block of video data comprising 224 the refmed group of pixels. PERFORM THE BIO PROCESS FOR THE BLOCK, BY DETERMINING A SINGLE MOTION VECTOR REFINEMENT FOR A GROUP OF PIXELS IN THE BLOCK AND REFINING THE GROUP OF PIXELS BASED ON THE SINGLE MOTION VECTOR REFINEMENT OUTPUT A BIO REFINED PREDICTIVE BLOCK OF VIDEO DATA COMPRISING THE REFINED GROUP OF PIXELS FIG. 21 [Continued on next page] DETERMINE THAT A BLOCK OF VIDEO DATA IS ENCODED USING A BI-DIRECTIONAL INTER PREDICTION MODE DETERMINE THAT THE BLOCK OF VIDEO DATA IS ENCODED USING A BIO PROCESS INTER PREDICT THE BLOCK OF VIDEO DATA USING THE BI-DIRECTIONAL INTER PREDICTION MODE 226 228 WO 2018/169989 Al MIDEDIMOMMIDEFIDIDEMIERCIMEHMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

INTER PREDICTION REFINEMENT BASED ON BI-DIRECTIONAL OPTICAL FLOW (BIO)

52280328_US

56282794_US,56524711_US,56424575_US,65641941_US,71792006_US,68099413_US

H04N 5/145,H04N 19/00,H04N 19/107,H04N 19/20,H04N 19/30,H04N 19/517,H04N 19/543,H04N 19/577,H04N 19/61,H04N 19/70

2001-09-25

N

A protein having activities of a human platelet activating factor acetylhydrolase, and represented by an amino acid sequence represented by the following formula (I) or an amino acid sequence having homology therewith; and a DNA encoding the protein: <table-cwu id='TABLE-US-00001'> <number>1</number> <table frame='none' colsep='0' rowsep='0' tabstyle='monospace'> <tgroup align='left' colsep='0' rowsep='0' cols='1'> <colspec colname='1' colwidth='217PT' align='left'/> <tbody valign='top'> <row> <entry></entry> </row> <row> <entry>Met Gly Val Asn Gln Ser Val Gly Phe Pro Pro Val</entry> </row> <row> <entry> </entry> </row> <row> <entry>Thr Gly Pro His Leu Val Gly Cys Gly Asp Val Met</entry> </row> <row> <entry> </entry> </row> <row> <entry>Glu Gly Gln Asn Leu Gln Gly Ser Phe Phe Arg Leu</entry> </row> <row> <entry> </entry> </row> <row> <entry>Phe Tyr Pro Cys Gln Lys Ala Glu Glu Thr Met Glu</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gln Pro Leu Trp Ile Pro Arg Tyr Glu Tyr Cys Thr</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gly Leu Ala Glu Tyr Leu Gln Phe Asn Lys Arg Cys</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gly Gly Leu Leu Phe Asn Leu Ala Val Gly Ser Cys</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Leu Pro Val Ser Trp Asn Gly Pro Phe Lys Thr</entry> </row> <row> <entry> </entry> </row> <row> <entry>Lys Asp Ser Gly Tyr Pro Leu Ile Ile Phe Ser His</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gly Leu Gly Ala Phe Arg Thr Leu Tyr Ser Ala Phe</entry> </row> <row> <entry> </entry> </row> <row> <entry>Cys Met Glu Leu Ala Ser Arg Gly Phe Val Val Ala</entry> </row> <row> <entry> </entry> </row> <row> <entry>Val Pro Glu His Arg Asp Arg Ser Ala Ala Thr Thr</entry> </row> <row> <entry> </entry> </row> <row> <entry>Tyr Phe Cys Lys Gln Ala Pro Glu Glu Asn Gln Pro</entry> </row> <row> <entry> </entry> </row> <row> <entry>Thr Asn Glu Ser Leu Gln Glu Glu Trp Ile Pro Phe</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Arg Val Glu Glu Gly Glu Lys Glu Phe His Val</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Asn Pro Gln Val His Gln Arg Val Ser Glu Cys</entry> </row> <row> <entry> </entry> </row> <row> <entry>Leu Arg Val Leu Lys Ile Leu Gln Glu Val Thr Ala</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gly Gln Thr Val Phe Asn Ile Leu Pro Gly Gly Leu</entry> </row> <row> <entry> </entry> </row> <row> <entry>Asp Leu Met Thr Leu Lys Gly Asn Ile Asp Met Ser</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Val Ala Val Met Gly His Ser Phe Gly Gly Ala</entry> </row> <row> <entry> </entry> </row> <row> <entry>Thr Ala Ile Leu Ala Leu Ala Lys Glu Thr Gln Phe</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Cys Ala Val Ala Leu Asp Ala Trp Met Phe Pro</entry> </row> <row> <entry> </entry> </row> <row> <entry>Leu Glu Arg Asp Phe Tyr Pro Lys Ala Arg Gly Pro</entry> </row> <row> <entry> </entry> </row> <row> <entry>Val Phe Phe Ile Asn Thr Glu Lys Phe Gln Thr Met</entry> </row> <row> <entry> </entry> </row> <row> <entry>Glu Ser Val Asn Leu Met Lys Lys Ile Cys Ala Gln</entry> </row> <row> <entry> </entry> </row> <row> <entry>His Glu Gln Ser Arg Ile Ile Thr Val Leu Gly Ser</entry> </row> <row> <entry> </entry> </row> <row> <entry>Val His Arg Ser Gln Thr Asp Phe Ala Phe Val Thr</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gly Asn Leu Ile Gly Lys Phe Phe Ser Thr Glu Thr</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Gly Ser Leu Asp Pro Tyr Glu Gly Gln Glu Val</entry> </row> <row> <entry> </entry> </row> <row> <entry>Met Val Arg Ala Met Leu Ala Phe Leu Gln Lys His</entry> </row> <row> <entry> </entry> </row> <row> <entry>Leu Asp Leu Lys Glu Asp Tyr Asn Gln Trp Asn Asn</entry> </row> <row> <entry> </entry> </row> <row> <entry>Leu Ile Glu Gly Ile Gly Pro Ser Leu Thr Pro Gly</entry> </row> <row> <entry> </entry> </row> <row> <entry>Ala Pro His His Leu Ser Ser Leu</entry> </row> </tbody> </tgroup> </table> </table-cwu>

en

Platelet activating factor acetylhydrolase, and gene thereof

5618737_JP

31762239_JP,19435894_JP,18489818_JP,19350016_JP

C12N 9/18

2018-02-22

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) W I P0 I P C T IiiimmomiolollmonolomonllnalionovoimIE (10) International Publication Number WO 2018/153343 Al (51) International Patent Classification: H03M 13/00 (2006.01) (21) International Application Number: PCT/CN2018/076970 (22) International Filing Date: 22 February 2018 (22.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2017/074381 22 February 2017 (22.02.2017) CN (71) Applicant: QUALCOMM INCORPORATED [US/US]; International IP Administration, 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). (72) Inventors; and (71) Applicants (for US only): YANG, Yang [CN/US]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). JIANG, Jing [CN/US]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). SARKIS, Gabi [CA/US]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). WEI, Chao [CN/CN]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). LI, Jian [CN/CN]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). SANKAR, Hari [US/US]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). XU, Changlong [CN/CN]; 5775 More- house Drive, San Diego, CA California 92121-1714 (US). SORIAGA, Joseph Binamira [US/US]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). (74) Agent: NTD PATENT & TRADEMARK AGENCY LIMITED; 10th Floor, Block A, Investment Plaza, 27 Jin- rongdajie, Xicheng District, Beijing 100033 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (54) Title: MUTUAL-INFORMATION BASED RECURSIVE POLAR CODE CONSTRUCTION 205 210 215 \'Transmitter/ Receiver Memory 220 Encoder/Decoder 225 FIG. 2 200 (57) : Methods, systems, and devices for wireless communication are described. To encode a vector of bits using a polar code, an encoder may allocate information bits of the vector to polarized bit-channels associated with a channel (e.g., a set of unpolar- ized bit-channels) used for a transmission. In some cases, the polarized bit-channels may be partitioned into groups associated with different values of some associated reliability metric (s). The information bits may be allocated to the polarized bit-channels based on the reliability metrics of the different polarized bit-channels and the overall capacity of a transmission. That is, the bit locations of a transmission may depend on the reliability metrics of different polarized bit-channels and the overall capacity of the transmission. To facilitate puncturing, the overall capacity of the transmission may be adjusted and the unpolarized bit-channels may be partitioned into polarized bit-channels based on the adjusted capacity. [Continued on next page] WO 2018/153343 Al MIDEDIMOMOIDEIREEM311011100MOMEHMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

MUTUAL-INFORMATION BASED RECURSIVE POLAR CODE CONSTRUCTION

52280328_US

73946143_US,68578736_CN,71201088_CN,56459191_US,74258152_US,57247260_US,69040232_CN,68749293_US

H03M 13/13,H03M 13/6362,H04L 1/0014,H04L 1/0047,H04L 1/0057,H04L 1/0068,H04L 5/0053

2018-07-13

N

40 -20 -10 6 35% 34 23 (12) INTERNATIONAL APPLICATION PUBLISHED (19) World Intellectual Property Organization International Bureau UNDER THE PATENT COOPERATION TREATY (PCT) IiiiionolivivivillEviiliololoillEvivivEmionvitiovois (10) International Publication Number WO 2019/014586 Al PCT (43) International Publication Date 17 January 2019 (17.01.2019) W I PO I Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (74) Agent: SHORE, David E. et al.; Choate, Hall & Ste- wart LLP, Two International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2018/042074 (22) International Filing Date: 13 July 2018 (13.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/532,889 14 July 2017 (14.07.2017) US (71) Applicant: CYTOMX THERAPEUTICS, INC. [US/US]; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (72) Inventors: DESNOYERS, Luc Roland; c/o CytomX Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). DUPAGE, Amy Grace; c/o CytomX Therapeutics, Inc., 151 Oyster (54) Title: ANTI-CD166 ANTIBODIES AND USES THEREOF Figure 13 Prevalence of CD166 Expression Across Metastatic Indications Number of cases scored -80+ cases Secondary Site 4 7 100-- — 178 % Strong /Mo dera te Exp ression 62 75 50 21 50 25 45 I I 51 71 25 0 e' S b 4 S cc` cc' 4' 9 + ..te s e\ t * 'b- A e t> e • 0 z 42<\' ci e ci° b 3 o <(% ,s 4 b *b c> „, t y , o t z e e e gf;. \ CP se e ( a. ckss s c> ez, kg ke as (20. €.> \ \ .tc` i e b 4, 0 'b. *A e e e e te b t e 43 43 ‘ 9 „ . 4 4 \ f t , c). cc• c° N t b- 2 b , e - - xe 16 t . 4 ‘ 3 Na .0 1-1 GC 71. 1-1 O 1-1 O (57) : The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capa- ble of binding CD 166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD 166 antibody or anti- gen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain (\'ICD\') of CD 166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166. In various embodiments, an anti-CD 166 antibody or antigen-binding polypep- tide is useful in a method of detecting or treating a condition or disease. [Continued on next page] WO 2019/014586 Al IIIIIIIIIIIIHNEHICIII111111111111111111111111111111111111111111111111111111 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

ANTI-CD166 ANTIBODIES AND USES THEREOF

56586992_US

77207219_US,76581761_US

A61K 47/6801,A61K2039/505,A61P 35/00,C07K 16/2803,C07K2317/24,C07K2317/515,C07K2317/565,C07K2317/622,C07K2317/76,C07K2317/92,G01N 33/56966,G01N 33/56972,G01N2333/70596

2017-10-18

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) - (19) World Intellectual Property Organization - - 1111111111111111111111111111111111111111111111111111111111111111111111111110111111 ' International Bureau (10) International Publication Number (43) International Publication Date ......0\'\' WO 2018/072705 Al 26 April 2018 (26.04.2018) WIP0 I PCT (51) International Patent Classification: Yuen Road, Shatin, New Territories, Hong Kong 999077 C12Q 1/68 (2006.01) (CN). (21) International Application Number: (74) Agent: INSIGHT INTELLECTUAL PROPERTY PCT/CN2017/106663 LIMITED; 19 A, Tower A, InDo Building, No. 48A (22) International Filing Date: Zhichun Road, Haidian District, Beijing 100098 (CN). 18 October 2017 (18.10.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/410,108 19 October 2016 (19.10.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicant: THE CHINESE UNIVERSITY OF HONG MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, KONG [CN/CN]; c/o Office of Research and Knowledge OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, Transfer Services, Room 301, Pi Ch'iu Building, Shatin, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, New Territories, Hong Kong 999077 (CN). TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: LO, Yuk-Ming Dennis; 4th Floor, 7 King Tak (84) Designated States (unless otherwise indicated, for every Street, Homantin, Kowloon, Hong Kong 999077 (CN). kind of regional protection available): ARIPO (BW, GH, _ CHIU, Rossa Wai Kwun; House 31, Double Haven, 52 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Ma Lok Path, Shatin, New Territories, Hong Kong 999077 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (CN). CHAN, Kwan Chee; Flat C, 15th Floor, Block 5, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Peak One, Mei Tin Road, Shatin, New Territories, Hong EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = Kong 999077 (CN). JIANG, Peiyong; Flat 7 on 1st Floor of MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = _ Block B of Kwong Lam Court, Nos. 62-66 (No.62) Siu Lek = (54) Title: GESTATIONAL AGE ASSESSMENT BY METHYLATION AND SIZE PROFILING OF MATERNAL PLASMA DNA = (57) : Temporal variations in one or more characteristics measured from 800 a cell-free DNA sample are used to estimate a gestational age of a fetus. Exam- — 810 ple characteristics include the methylation level measured from the cell-free DNA sample, size of DNA fragments measured from the cell-free DNA sample (e.g., = Arialysits ere-free DNA isoleasks Pisa a Siuttple to determine whether the cell-free DNA molecule is proportion of fetal-derived DNA fragments longer than a specified size), and end- = = — Methylated At one mmotn Sites. ing patterns of the DNA fragments align to a reference genome. =8ID Determine arespectivertumber of cell-free DNA —_ oloteculea thar aremedaylated at each of the one ormore sites = = = — Calculate ameasund methylation level of cell-free DNA = Moleattlea in the sample = Obtain ate or more tatibtathin data pokis Shag speedy a gestational age corresponding to a calibration methylation level 11 850 in Compare the measured metbylation Level to a calibratima medtgladon level of at kart one calibration data points IN 11 © g6 1 N Estimate a gestational age of the fetus based owthe Ir----- comparison © 1-1 Fig. 8 0 N O [Continued on next page] WO 2018/072705 Al MIDEDIMOMMIDIREIHNIFIHMEIIMERVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

GESTATIONAL AGE ASSESSMENT BY METHYLATION AND SIZE PROFILING OF MATERNAL PLASMA DNA

56200690_CN

56378466_CN,56146821_CN,56274289_CN,56377450_CN

C12N 15/1003,C12Q 1/6858,C12Q 1/6883,C12Q 1/6888,C12Q2600/154,G01N 33/53

2018-03-30

N

ModemCommunications Component 190 Assignment Receiving Component 192 UCI Transmitting Component 194 100 • aTN --------- • ---- --• --------- 115 120 135 1 1 505 125 -V. 130 130 FIG. 1 Modem 140 Communications Component 150 Determining Component 152 Cyclic Shifts Determining Component 154 Assigning Component 156 Receiving Component 158 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIPO I PCT o °nolo VIII HE °um oimIE (10) International Publication Number WO 2018/194821 Al (51) International Patent Classification: HO4L 1/00 (2006.01) H04L 5/00 (2006.01) HO4L 1/18 (2006.01) (21) International Application Number: PCT/US2018/025524 (22) International Filing Date: 30 March 2018 (30.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/486,414 17 April 2017 (17.04.2017) US 15/940,710 29 March 2018 (29.03.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: WANG, Renqiu; c/o QUALCOMM INCOR- PORATED, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). PARK, Seyong; c/o QUALCOMM IN- CORPORATED, 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). XU, Hao; c/o QUALCOMM IN- CORPORATED, 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). HUANG, Yi; c/o QUALCOMM INCORPORATED, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: BINDSEIL, James J. et al.; c/o ARENT FOX LLP, 1717 K Street NW, Washington, District of Columbia 20006-5344 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (54) Title: MULTIPLEXING FOR SEQUENCE BASED ACKNOWLEDGEMENT DESIGN FOR NEW RADIO 71' 00 11 00 11 O C (57) : A method and apparatus for improved transmission of ACK and NACK bits to a base station The example method may determine a distance between a first UE and a second UE based on one or more of a sequence length, a number of hypothesis, or a number of UEs sharing an OFDM symbol. The example method may determine a plurality of cyclic shifts for each of the first UE and the second UE. The example method may assign one or more sequences to each UE. The example method may receive, at the base station, a multiplexed signal, wherein the multiplexed signal includes at least one bit of uplink control information (UCI) from the first UE and the second UE multiplexed on an uplink short burst transmitted via the OFDM symbol. The method may enable the receipt of UCI from multiple UEs in a multiplexed signal. [Continued on next page] WO 2018/194821 Al IIMEDIMOMOIDEIREEMOMOICEDIVEINIMEn KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

MULTIPLEXING FOR SEQUENCE BASED ACKNOWLEDGEMENT DESIGN FOR NEW RADIO

52280328_US

74268558_US,71547434_US,69235791_US,56570006_US

H04J 1/02,H04L 1/0073,H04L 1/1861,H04L 5/0007,H04L 5/0048,H04L 5/0055,H04W 72/0413,H04W 72/12,H04W 88/02,H04W 88/08

2017-08-22

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property :::` , 1111111011110111011111111111011111010111111111101110111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....•\'\' WO 2018/080624 Al 03 May 2018 (03.05.2018) W I PO I PCT (51) International Patent Classification: NARAYANASWAMI, Ravi; 1600 Amphitheatre Park- G06N 3/10 (2006.01) way, Mountain View, California 94043 (US). (21) International Application Number: (74) Agent: HENRY, Joel et al.; Fish & Richardson P.C., P.O. PCT/US2017/047992 Box 1022, Minneapolis, Minnesota 55440-1022 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 22 August 2017 (22.08.2017) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (25) Filing Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (26) Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (30) Priority Data: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 15/336,066 27 October 2016 (27.10.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 15/465,774 22 March 2017 (22.03.2017) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (71) Applicant: GOOGLE LLC [US/US]; 1600 Amphitheatre SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, Parkway, Mountain View, California 94043 (US). TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: WOO, Dong Hyuk; 1600 Amphitheatre (84) Designated States (unless otherwise indicated, for every Parkway, Mountain View, California 94043 (US). kind of regional protection available): ARIPO (BW, GH, (54) Title: EXPLOITING INPUT DATA SPARSITY IN NEURAL NETWORK COMPUTE UNITS 300-- INSTRUCTIONS, INPUT ACTIVATIONS, AND WEIGHTS/PARAMETERS 303--- t Bitmap 1 1 ° 1 1 1 6 1 1 1 ° 1 1 1 ° ( 1 ) ( ) 3 + ( ) 5 ( ) 7 Weights and Partial Sums (Second Memory 110) Controller 302 310 First Activiations 102 Memory 108 Input 310 310 Activation Bus Parameters MAC 304 T r104a f Parameters MAC 304 r104b IL f Parameters MAC 304 r104c 306 —2 Output Activation Bus I 1 , 308 305 -- UU1 t. EI1 i ,-1 .4 I I - (57) : A computer el a controller of the computing device, whether each of the input activations has either a zero value or a non-zero value. The method 0 further includes storing, GC © activation includes generating - non-zero values. The GC ,_ 1 onto a data bus that is © memory address location N ( 1 ) ( ) 3 ( 5 ) ( ) 7 FIG. 3 -implemented method includes receiving, by a computing device, input activations and determining, by in a memory bank of the computing device, at least one of the input activations. Storing the at least one input an index comprising one or more memory address locations that have input activation values that are method still further includes providing, by the controller and from the memory bank, at least accessible by one or more units of a computational array. The activations are provided, at least associated with the index. one input activation in part, from a C [Continued on next page] WO 2018/080624 Al MIDEDIMOMMIDIREEMOOMMMONEDIDEHMEMOIMIE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(U)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))

en

EXPLOITING INPUT DATA SPARSITY IN NEURAL NETWORK COMPUTE UNITS

57394858_US

56430398_US,56432157_US

G06F 9/3001,G06F 9/38,G06F 9/3824,G06F 13/1668,G06F 15/76,G06F 17/16,G06N 3/0454,G06N 3/063,G06N 3/08,G06N 3/10,G06N 5/04,G06N 20/00,G06N 20/10,Y02D 10/00

2019-06-14

Y

(19) til-S-01AM,1 -J r 9i0d (19) 1111DIIIIIIIII~Ilili 111111111 I N11111111111 INi (10) (4 3) [AM EPI 2020O11q 19 E (19.11.2020) WO 2020/230340 A1 WIPOlPCT (51) )- : (72)RHj :#(1 T[](ITOKazuhiko); T0640804-l G06T 7/00 (2017.01) V L6 L IN 1 $ E M H 5 7 T H 6 (21) ISl P : PCT/JP2019/023674 $I 74 1'Y IF] Hokkaido (JP). I& Sil, (SATOMakoto); ~0640804 (22) pfl 5 r, :f AE 20199 *6)A14 H (14.06.2019) -l FP 5 FX -A Vq *N 7 T H 6 T1 4- A $:z:' (25) 5 0) : ,* - v'Y NHokkaido (JP). (26) 8 gga (74) ftdT)A : -2 0E r. NijE A (KOIWA Nobuhide et _.0 al.); T2850859 ~:F M * Ifft ? -A.-- J' HR 3 - 1 7Chiba (JP). *R#J 2019-090719 2019*5)J13H(13.05.2019) JP (8 1) ILE_ ZP (Ai PR Gglj) , c WA( 0) P9|AJ 1 (71)-1- - $ 47 M '(MICRONET 9% -Ji): AE, AG, AL, AM, AO, AT, AU, AZ, CO. LTD.) [JP/JP]; T0640804 -lbfU L M$ $ BA, BB, BG, BH, BN, BR, BW. BY, BZ, CA, CH, -5E K(AN 7 T 6 AHokkaido (JP). CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (54) Title: FACIAL RECOGNITION SYSTEM, FACIAL RECOGNITION METHOD, AND FACIAL RECOGNITION 3 Computer at facial authentication processing site 0- t -1 Camera 21 Reception operationexecutigunit 22 Human detection processing unit -23 Ruin-mask-comparisonaunit 24 Poin mask registering uit ____________________25 Outgongfacialimage transmittingunit 26 Com ing facial authentication restreceiving nit SNW1 Internet A Open ngt on ec i itydour CC De tectio n ofsuspiciousperson S(57) Abstract: Provided is afacialrecognition technique with which itis possible to determine false detection of afacial regionathighspeedandtoperformhighlyaccuratefacialrecognition.Thisfacialrecognition system comprises first facialdetectionmeans2havingarelativelylowaccuracyfor performing humanfacial detectionfroma cameraimage 201,andasecondfacialdetectionmeans3forperforminghuman2facial detction withhigheraccuracywith rspecttothe camera image 201. Facial detection isperfored withiuspect teach camera image obtained beach of thefirst facial W O 2020/23 0340 A41111 1 ||||||||||||||||||||||||||||||||||||i|III||||||||||||||||||||||||||||||||||||| |ill| HN, HR, HU, ID, IL, IN, IR, IS, JO, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 9iht WNE): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), - -5 7 (AM, AZ, BY, KG, KZ, RU, TJ, TM), 9 - F-1 /' (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). - Wip!tW} (M* 21(3)) detection means 2 and the second facial detection means 3. If the second facial detection means 3 is unable to perform facial detection with respect to a facial region detected by the first facial detection means 2, it is determined that the first facial detection means 2 has made a false detection, and the center of gravity coordinates of the facial region are learned as a point mask position. Thereafter, when the first facial detection means 2 has performed facial detection from the camera image 201, the center of gravity coordinates of the facial region is determined. If matching coordinates are found in a group of stored point mask coordinates, the region is determined to be a false detection region, and the highly accurate facial detection by the second facial detection means 3 is not performed with respect to the captured image. 2t0t )5tt 6jAAS&JJ/51 - tttd ZttLVzn 1-eHk0) M PA )10&ff --f 't#L, i2 0 1t t tctt AT QL{ 9EtZkt )1,0& ~ - )0 &fl- ' )A #fiTfI, )O#fI,3L0 tL tEJ1 - lM 7 l-:{itz , , CO2f ,M1 6D A$t4k tf E ISTzRL b t4>fiLkfvi 1:14JLZ- 2 0) PA#43(J -f&3tAO',-'-X SO A&',---F - , A H-' Lkt0

en

Face recognition system, face recognition method and face recognition program

52026390_JP

13227950_,15998049_

G06F 3/14,G06K 9/6262,G06V 10/22,G06V 10/98,G06V 20/52,G06V 40/161,G06V 40/166,G06V 40/172,G07C 9/00563

2018-08-16

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) vitivio VIII oviolo olimilooliommoitio Hs (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2019/034753 Al (43) International Publication Date 21 February 2019 (21.02.2019) WIP0 I PCT (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/40 (2006.01) CO7K 16/28 (2006.01) (21) International Application Number: PCT/EP2018/072272 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art 21(3)) with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 16 August 2018 (16.08.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/546,336 16 August 2017 (16.08.2017) US 62/582,609 07 November 2017 (07.11.2017) US (71) Applicant: TUSK THERAPEUTICS LTD [GB/GB]; Stevenage Bioscience Catalyst, Accelerator Building, Gun- nels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). (72) Inventors: GOUBIER, Anne; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). SALIMU, Josephine; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hert- fordshire SG1 2FX (GB). GOYENECHEA, Beatriz; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). MERCHIERS, Pascal; c/o Tusk Therapeutics Lim- ited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). MOULDER, Kevin; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hertford- shire SG1 2FX (GB). EISSLER, Nina; c/o Tusk Therapeu- tics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). FILOSTO, Simone; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hertford- shire SG1 2FX (GB). BARUAH, Hemanta; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). PRINZ, Bianka; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). (74) Agent: LEONARD, Thomas Charles et al.; Kilburn & Strode LLP, Lacon London, 8 Theobalds Road, London London WC1X 8NL (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (54) Title: CD38 ANTIBODY (57) : The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.

en

CD38 ANTIBODY

76534723_GB

77428845_GB,57667501_US,77142286_US,73527263_GB,76255639_GB,74005832_GB,73401696_GB,73433560_GB,74005848_GB

A61K 39/39558,A61K2039/507,A61P 35/00,C07K 16/2896,C07K 16/40,C07K2317/56,C07K2317/565,C07K2317/732,C07K2317/734,C07K2317/92

2017-10-27

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property C.--.` MD HIM 011101011M 01 11010101111111111011110011101101110111 OEN Organization International Bureau (10) International Publication Number 03 (43) International Publication Date ......P' WO 2018/081640 Al 03 May 2018 (03.05.2018) WIP0 I PCT (51) International Patent Classification: Sciences LLC, 269 East Grand Ave., South San Francis- GOOF 19/00 (2011.01) GOOK 9/62 (2006.01) co, California 94080 (US). KRISHNAN, Dilip; c/o Verily GOOK 9 / 4 6 (2006.01) G06T 7/00 (2017.01) Life Sciences LLC, 269 East Grand Ave., South San Fran- GOOK 9 / 5 2 (2006.01) cisco, California 94080 (US). L1VNI, Josh; c/o Verily Life Sciences LLC, 269 East Grand Ave., South San Francis- (21) International Application Number: PCT/US2017/058872 co, California 94080 (US). DESNOYER, Mark; c/o Verily Life Sciences LLC, 269 East Grand Ave., South San Fran- (22) International Filing Date: cisco, California 94080 (US). 27 October 2017 (27.10.2017) (74) Agent: MCALLISTER, Tyler et al.; Kilpatrick Townsend (25) Filing Language: English & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, N.E., Suite 2800, Atlanta, Georgia 30309 (26) Publication Language: English (US). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 62/414,597 28 October 2016 (28.10.2016) US kind of national protection available): AE, AG, AL, AM, (71) Applicant: VERILY LIFE SCIENCES LLC [US/US]; AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 269 East Grand Ave., South San Francisco, California CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 94080 (US). DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (72) Inventors: ZHA, Tiantian; c/o Verily Life Sciences LLC, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, — 269 East Grand Ave., South San Francisco, California MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 94080 (US). OVADIA, Yaniv; c/o Verily Life Sciences OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = LLC, 269 East Grand Ave., South San Francisco, Califor- nia 94080 (US). NEWBURGER, Daniel; c/o Verily Life = = (54) Title: PREDICTIVE MODELS FOR VISUALLY CLASSIFYING INSECTS = = = 102 1, 1 . 104 - 1 6 — _.I _ 108 ACCESS 114 AN WAGE DEPICTING PLURALITY OF INSECTS 112 — = = 1208 I-120N 1145 114N .._ _. • IDEN1IFY PATCH FROM MAT DEPICTS INSECT= AN IMAGE THE IMAGE AN = = = 106 = USE A PREILTAIE - i = PREDICTIVE MODE JIQ MOOEL TO EVALUATE IMAGE PATCH TO „)[ACRE INSECT(S). CLASSTY INSECT(S), AND/OR COUNT 106 iNsEcr(s)j22 11 .4 © 71' V; JJ 06 OUTPUT INSECT IN FROM THE PREDICTIVE MODEL CORRESPOIOING 10 THE EVALUATION OF THE IMAGE PATCH 124 11 GC FIG. 1 © . --- - GC (57) : Insects can be localized and classified using a predictive model. To begin, image data is obtained that corresponds to the 1 -1 insects.. Using a predictive model, samples of the image data are evaluated to determine whether the image portions include an insect 0 and, if so, into what category the insect should be classified (e.g., male/female, species A/species B, etc.). ei o [Continued on next page] WO 2018/081640 Al MIDEDIMOMMIDIRERIONEHOHINHOIHMEEN SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

PREDICTIVE MODELS FOR VISUALLY CLASSIFYING INSECTS

67553017_US

71263558_US,71308527_US,71920996_US,71938436_US,71808567_US,71883505_US

G05B 13/027,G05B 13/048,G06K 9/6267,G06K 9/627,G06N 3/0454,G06N 3/082,G06N 3/084,G06T 7/0002,G06T 7/0004,G06T2207/20081,G06T2207/20084,G06V 10/255,G06V 10/764,G06V 10/82,G06V2201/06

2017-10-17

N

FIGURE 5 Encode all source chunks at predetermined visual quail), level to determine corresponding encoded bitrates 504 Generate cumulative distribution function (CDF) of encoded bitrates 506 W O 20 18/075 465 Al Determine NI representative bitrate-quality points based on the M representative pre-encodes 512 Fit logarithmic curve to NI representative bitrate-quality points to construct a representative bitrate- quality curve 514 Set lambda to slope of tangent to representative bitrate-quality curve at representative bitrate 516 Select representative chuck and representative bitrate based on the CDF and a predetermined percentile 508 For representative chunk, generate a representative pre-encode at each of M predetermined quality levels 516 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 April 2018 (26.04.2018) WIP0 I PCT ill~~~~~~~~ 011101010VIIIOH olo mom loominiflom oimIE (10) International Publication Number WO 2018/075465 Al (51) International Patent Classification: HO4N 21/2343 (2011.01) H04N 21/845 (2011.01) (21) International Application Number: PCT/US2017/056902 (22) International Filing Date: 17 October 2017 (17.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/296,580 18 October 2016 (18.10.2016) US (71) Applicant: NETFLIX, INC. [US/US]; 100 Winchester Circle, Los Gatos, California 95032 (US). (72) Inventors: DE COCK, Jan; 100 Winchester Circle, Los Gatos, California 95032 (US). AARON, Anne; 100 Win- chester Circle, Los Gatos, California 95032 (US). (74) Agent: CAREY, John C. et al.; Artegis Law Group, LLP, 7710 Cherry Park Drive, Suite T104, Houston, Texas 77095 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: CONSTANT-SLOPE BITRATE ALLOCATION FOR DISTRIBUTED ENCODING (57) : In one embodiment of the present invention, a bitrate allocation engine allocates bitrates for distributed encoding of source data. Upon receiving a chunk of source data, the bitrate allocation engine generates a curve based on multiple points that each specify a different visual quality level and corresponding encoding bitrate for encoding the chunk. Subsequently, the bitrate allocation engine com- putes an optimized encoding bitrate based on the generated curve and an optimization factor that is associated with different visual quality levels and corresponding encoding bitrates for multiple chunks of the source data. The bitrate allocation engine then causes the chunk to be encoded at the optimized encoding bitrate. Advantageously, the re- sulting encoded chunk is optimized with respect to the optimization factor for multiple chunks of the source data.

en

CONSTANT-SLOPE BITRATE ALLOCATION FOR DISTRIBUTED ENCODING

56583058_US

68847351_US,71533143_US

H04N 19/184,H04N 19/21,H04N 21/234354,H04N 21/23439,H04N 21/8456

2018-02-09

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT omit VIII °nolo VIII iflo oimIE (10) International Publication Number WO 2018/148585 Al (51) International Patent Classification: C07K 16/40 (2006.01) (21) International Application Number: PCT/US2018/017680 (22) International Filing Date: 09 February 2018 (09.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/457,722 10 February 2017 (10.02.2017) US (71) Applicant (for all designated States except AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR): GENEN- TECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US). (71) Applicant (for AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR only): F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). = (72) Inventors: CHEN, Xiaocheng; 1 DNA Way, South San Francisco, CA 94080-4990 (US). DENNIS, Mark; 1 DNA Way, South San Francisco, CA 94080-4990 (US). JACK- MAN, Janet; 1 DNA Way, South San Francisco, CA 94080-4990 (US). KOERBER, James, T.; 1 DNA Way, South San Francisco, CA 94080-4990 (US). LU, Mason; 5015 Darnell St., Houston, TX 77096 (US). MAUN, Hen- ry, R.; 1 DNA Way, South San Francisco, CA 94080-4990 (US). RAJAPAKSA, Kathila; 1 DNA Way, South San Francisco, CA 94080-4990 (US). RAMANUJAN, Saroja; 1 DNA Way, South San Francisco, CA 94080-4990 (US). STATON, Tracy; 1 DNA Way, South San Francisco, CA 94080-4990 (US). WU, Lawren; 1 DNA Way, South San Francisco, CA 94080-4990 (US). YI, Tangsheng; 1 DNA Way, South San Francisco, CA 94080-4990 (US). (74) Agent: ELBING, Karen, L.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 1-1 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 1 1 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 71' 1-1 013 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 1-1 (54) Title: ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF (57) : The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as 0 well as methods of using the same.

en

ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF

55221849_US

67509691_US,73552939_US,74037580_US,64871504_US,74128729_US,73969440_US,73513679_US,71935521_US,73538968_US,73508553_US,55573664_US

A61K 39/3955,A61K 39/39591,A61K 45/06,A61K 47/10,A61K 47/183,A61K 47/22,A61K 47/26,A61K2039/505,A61P 1/04,A61P 3/04,A61P 7/00,A61P 11/00,A61P 11/02,A61P 11/06,A61P 11/14,A61P 17/00,A61P 17/04,A61P 17/06,A61P 19/02,A61P 29/00,A61P 37/04,A61P 37/08,A61P 43/00,C07K 16/244,C07K 16/40,C07K2317/24,C07K2317/31,C07K2317/34,C07K2317/40,C07K2317/55,C07K2317/56,C07K2317/565,C07K2317/567,C07K2317/76,C07K2317/92,C07K2317/94,C12N 15/63,C12Y 304/21059

2001-05-23

N

A system is disclosed that provides an interactive rewards-based method that uses a protocol for instructional response in order to provide a motivating, individualized educational and entertaining experience. The system utilizes an interface through a computer. The system offers the user (a.k.a. student) simulated environments that represent different realities and an opportunity to solve interesting problems and learning puzzles. When the user inputs a response this calls forth a system response using the built-in Intelligent Mentor, thereby teaching the user. The iterative response process provides the user opportunities to discovery before proceeding to a higher level of the subject material. The pedagogical system uses neural nets (engine of artificial intelligence) that drive responses that are synchronized to typographical and graphical illustrations and/or pictorial illustrations used to simulate reality and to provide dynamic interactions. Stages of progression are integrated into the pedagogical system in order to provide users with individually paced experiences determined by the level of difficulty and rate of performance per time period. Users' interaction involves real-time decision-making and fusion of the educational material. It involves programs in computer medium that create a rewards-based system to provide a motivating educational and/or entertainment environment including natural attractions that further motivate continuous involvement in the learning process. Encoded lessons are enabled in the system that provide feedback on aspects of user performance such as mission management, mathematical solutions, recognition, matching, and utilizing data to solve problems and puzzles. The user receives credits each time he/she successfully completes a section. Credits are additive and may be exchanged for material rewards by using this invention of the 'virtual mall' for the computer network. The rewards redemption system includes a server in communication with the users computer mechanism to form a network that may include the Internet. The credits may be saved or can be exchanged for material reward certificates. If redeemed, the student player is dispensed a specific verifiable reward acknowledgement. The computer system can also provide for competition games played for a rivalry of credits by a number of users. Reward information, such as reward costs in terms of specific credit redemption is automatically determined by the system. While this invention has been described in terms of several embodiments, it is contemplated that alterations, variations and equivalents thereof will become apparent to those skilled in the art of pedagogy upon a reading of the specification and study of the drawings. For example, many types of problems/solution sets and puzzles can be provided for use with the disclosed rewards based system, and the computer tool can be utilized for classroom teaching as well. Thus variations can be used. It is noted that the rewards-based system of redemption can be implemented on a single computer connected to other computers, with or without use of the Internet. However, the preferred embodiment illustrated here envisions that the invention will be used in a broad network such as the Internet. The provision of rewards can be achieved by redemption certificates or electronically. It is therefore intended that the claims include all such alterations, variations, and equivalents as fall within the spirit and scope of the present invention. This rewards-based pedagogical system offering lessons within simulated environments and providing for various reward redemptions represents advancement in pedagogical systems for computer-assisted learning and paradigms of progressive skill-development.

en

Interactive rewards-based pedagogical system using an engine of artificial intelligence

39597805_

39597806_US

G09B 19/00

2018-04-03

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT O V SID o Ho mil mil m11°1111E1° VII IE (10) International Publication Number WO 2018/178396 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/058479 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/479,712 31 March 2017 (31.03.2017) US PCT/EP2018/057836 27 March 2018 (27.03.2018) EP (71) Applicant: GENMAB HOLDING B.V. [NL/NL]; Upp- salalaan 15, 3584 CT Utrecht (NL). (72) Inventors: OOSTINDIE, Simone; c/o Genmab B.V. Upp- salalaan 15, 3584 CT Utrecht (NL). BEURSKENS, Frank; c/o GENMAB B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). BREIJ, Esther; c/o Gebmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). VAN DEN BRINK, Edward; c/o Gen- mab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). HOL- LENSTEIN, Andreas; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). OVERDIJK, Marije; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). LINDOR- FER, Margaret; 276 Spring Meadow Lane, Keswick, Vir- ginia 22947 (US). TAYLOR, Ronald; 276 Spring Mead- ow Lane, Keswick, Virginia 22947 (US). PARREN, Paul; Werdorperwaard 17, 3984 PR Odijk (NL). VAN DER HORST, Hilma; Schoolstraat ibis, 3581 PM Utrecht (NL). E.D. CHAMULEAU, Martine; VU University Medical Center Department of Hematology De Boelelaan 1117, 1081 HV Amsterdam (NL). MUTIS, Tuna; VU University Medical Center De Boelelaan 1117, Building CCA, 4.022, 1081 HV Amsterdam (NL). SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 1-1 t:T GC N 1-1 00 O 1-1 N C (74) Agent: GENMAB A/S; Kalvebod Brygge 43, DK-1560 Copenhagen V (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF (57) : CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

en

BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF

74314400_NL

71232504_NL,74198537_NL,57642238_NL,56521079_NL,74191430_US,73943439_US,56436408_NL,56520644_NL,74245139_NL,73740483_NL,74173349_NL,73740701_NL

A61K 49/00,A61K2039/505,A61K2039/507,A61K2039/545,A61P 35/00,C07K 16/2887,C07K 16/2896,C07K2317/21,C07K2317/24,C07K2317/31,C07K2317/34,C07K2317/526,C07K2317/565,C07K2317/72,C07K2317/732,C07K2317/734,C07K2317/92,C07K2317/94,G01N 33/68,G01N2333/70596

2017-08-29

N

InstructionSet, Activations, Weights Processing Unit 102 Storage Medium 104 Computing System MAC 108 (Linear Unit) Activation Unit 110 122 Tensor Status Elements Instruction Buffer (Tensor / DMA) 124 Tensor Traversal Unit 106 First Bank (Activations) 112-' 1 Second Bank (Weights) 114— ) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIP0 I PCT omit VIII °nolo III m 1111 0111 CIO iflo (10) International Publication Number WO 2018/080628 Al (51) International Patent Classification: GOON 3/04 (2006.01) GOON 3/063 (2006.01) (21) International Application Number: PCT/US2017/049165 (22) International Filing Date: 29 August 2017 (29.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/336,216 27 October 2016 (27.10.2016) US 15/455,685 10 March 2017 (10.03.2017) US (71) Applicant: GOOGLE LLC [US/US]; 1600 Amphitheatre Parkway, Mountain View, California 94043 (US). (72) Inventors: NARAYANASWAMI, Ravi; 1600 Amphithe- atre Parkway, Mountain View, California 94043 (US). WOO, Dong Hyuk; 1600 Amphitheatre Parkway, Moun- taro View, California 94043 (US). TEMAM, Olivier; 8 Rue de Londres, 75009 Paris (FR). KHAITAN, Harshit; 1600 Amphitheatre Parkway, Mountain View, California 94043 (US). (74) Agent: HENRY, Joel et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (54) Title: NEURAL NETWORK INSTRUCTION SET ARCHITECTURE 100 Output FIG. 1 (57) : A computer-implemented method that includes receiving, by a processing unit, an instruction that specifies data values for performing a tensor computation. In response to receiving the instruction, the method may include, performing, by the processing unit, the tensor computation by executing a loop nest comprising a plurality of loops, wherein a structure of the loop nest is defmed based on one or more of the data values of the instruction. The tensor computation can be at least a portion of a computation of a neural network layer. The data values specified by the instruction may comprise a value that specifies a type of the neural network layer, and the structure of the loop nest can be defmed at least in part by the type of the neural network layer. [Continued on next page] WO 2018/080628 Al MIDEDIMOMOIDEIREEMOOMMMONIIMEHMEEN (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))

en

NEURAL NETWORK INSTRUCTION SET ARCHITECTURE

57394858_US

71255969_FR,56430398_US,71835542_US,56432157_US

G06F 9/30,G06F 13/28,G06N 3/02,G06N 3/04,G06N 3/0454,G06N 3/063,G06N 20/00

2017-07-11

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111411 0 11101 HOE 100011101M 01011101111101111011 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\'\'\'1 WO 2018/071079 Al 19 April 2018 (19.04.2018) WIP0 1 PCT _ (51) (21) (22) (25) Filing Language: (26) (30) International Patent Classification: PCT/US2017/017841 GOOF 3/00 (2006.01) GOOF 17/30 (2006.01) 14 February 2017 (14.02.2017) US GOOF 3/048 (2013.01) GOOF 19/00 (2011.01) GOOF 9 / 4 6 (2006.01) GOOF 19/28 (2011.01) (71) Applicant: GENOMSYS SA [CH/CH]; Chemin de la Raye 13, 1024 Ecublens VD (CH). International Application Number: PCT/US2017/041585 (72) Inventor; and (71) Applicant: BALUCH, Mohamed Khoso [US/US]; 4439 International Filing Date: Woodsedge Ct, Chantilly, VA 20151 (US). 11 July 2017 (11.07.2017) (72) Inventors: ALBERTI, Claudio; Chemin des Esserts 1, English 1213 Petit-Lancy (CH). ZOIA, Giorgio; Chemin des Croix- Publication Language: English Rouges 10, 1007 Lausanne (CH). RENZI, Daniele; Route Aloys-Fauquez 105, 1018 Lausanne (CH). Priority Data: (74) Agent: BILICKI, Byron et al.; The Bilicki Law Firm, P.C., PCT/EP2016/074297 1285 North Main Street, Jamestown, NY 14701 (US). 11 October 2016 (11.10.2016) EP PCT/EP2016/074301 (81) Designated States (unless otherwise indicated, for every 11 October 2016 (11.10.2016) EP kind of national protection available): AE, AG, AL, AM, PCT/EP2016/074307 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 11 October 2016 (11.10.2016) EP CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, PCT/EP2016/074311 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 11 October 2016 (11.10.2016) EP HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/US2017/017842 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 14 February 2017 (14.02.2017) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = = Title: 7! an mapped -- -- GC proposed 0 unaligned METHOD AND SYSTEMS cluster 1 -- , r / \ Signature 1 I FOR THE , l ‘ \ cluster Signature 2 INDEXING OF BIOINFORMATICS DATA \ cluster -,„ , / - ,,,, f I' I 1 ' \ \ \ \ / I/ K \ Sfrmature K • 2 The reads cluster common (signature) \c:uster M Signature M in each share a sequence Signatures can have either constant or variable length sequencing machines. The those sequence reads that cannot a method to partition and index = (54) = _ _ = = = — — = = = - = = _ 1-1 .4 Cl' It-- 0 1-1 It-- c:::: , (57) ,—I be ei C ACGT...GTG ATCT... G CC . Giai,2T...ATA AGTT...AAG : Method and apparatus for the indexing of genome sequence data produced by genome method can be applied both to raw sequence data produced by sequencing machines and to on any reference sequence according to specific matching criteria. This invention describes sequence reads to enable browsing and efficient selective access. [Continued on next page] WO 2018/071079 Al MIDEDIMOMOIDEIREIDIONOMMINECIONVOIMIE OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the identity of the inventor (Rule 4.17(i)) Published: — with international search report (Art. 21(3))

en

METHOD AND SYSTEMS FOR THE INDEXING OF BIOINFORMATICS DATA

71256224_CH

71103226_CH,71896073_CH,71645555_CH,71717751_US

G06F 3/048,G06F 7/00,G06F 16/2282,G06F 16/2365,G06F 16/285,G06F 21/602,G06F 21/6218,G06F 21/6245,G16B 20/10,G16B 20/20,G16B 30/00,G16B 30/10,G16B 30/20,G16B 40/00,G16B 40/10,G16B 45/00,G16B 50/00,G16B 50/10,G16B 50/30,G16B 50/40,G16B 50/50,G16B 99/00,H03M 7/3086,H03M 7/70